Podcasts about Molecular pathology

Metabolic dysfunction-associated steatotic liver disease (MASLD), also known as fatty liver disease, is a chronic liver condition that affects nearly 1 in 3 people worldwide. It is closely linked to obesity, type 2 diabetes, and metabolic syndrome. Unchecked, it can progress to a more severe form of disease called Metabolic Dysfunction-Associated Steatohepatitis (MASH). Prognosticating the risk of disease progression in MASLD and MASH has traditionally involved liver biopsy, a process that involves removing a tissue sample with a hollow needle and then examining the sample under a microscope to diagnose and stage disease. However, biopsy has many limitations. Additionally, drug development for MASLD and MASH has proceeded slowly in part due to a reliance on liver biopsy to determine drug efficacy.Recently, increasing evidence is suggesting that non-invasive options, for example, imaging examinations along with blood tests that assess likelihood of disease progression such as the Enhanced Liver Fibrosis (ELF) Test, may effectively reduce the need for the more invasive alternative. Key experts in MASLD and MASH share their perspectives about how clinical evidence supports a shift in the way patients with MASLD and MASH could be evaluated in clinical practice and in research.Host Matt Gee, Director of Collaborations and External Engagement at Siemens Healthineers, is joined by Prof. William Rosenberg, Deputy Director of the Institute for Liver and Digestive Health at University College London as well as Dr. Veronica Miller, Director of the Forum for Collaborative Research at the University of California, Berkeley School of Public Health; Dr. Arun Sanyal, Professor of Medicine, Physiology, and Molecular Pathology in the Division of Gastroenterology at Virginia Commonwealth University; and Dr. Michelle Long, International Medical Vice President of Metabolic Dysfunction-Associated Steatohepatitis at Novo Nordisk and Associate Professor in the Section of Gastroenterology and Hepatology at Boston University.What you'll learn in this episode:Liver biopsy creates several obstacles for patients and has limitationsDrug development faces challenges by the reliance on biopsy as a measure of treatment effectivenessNon-invasive tools may be suitable alternatives to liver biopsy both in clinical practice and in drug developmentConnect with Matt GeeLinkedIn Connect with Veronica MillerLinkedInConnect with William RosenbergLinkedInConnect with Michelle LongLinkedInConnect with Arun SanyalVCU.edu Hosted on Acast. See acast.com/privacy for more information.

A reversible liver condition is the fastest growing cause of liver transplantation in Western countries: Metabolic dysfunction-associated steatotic liver disease—or MASLD—affects patients worldwide. It's characterized by excessive fat accumulation in the liver and can progress into more severe forms of liver disease, potentially resulting in fibrosis, cirrhosis and liver failure.Risk factors for developing liver disease include obesity, insulin resistance, type 2 diabetes, and metabolic syndrome. Genetics, unhealthy dietary habits, and a sedentary lifestyle can also play significant roles in its development. Diagnosis typically involves imaging examinations along with blood tests that assess liver function and rule out other causes of liver disease.Disease management focuses on lifestyle modifications such as diet and exercise, though new medications are now being prescribed to slow and potentially reverse this condition. Regular monitoring of disease progression is also crucial for successful treatment.In this episode, experts in the field of liver disease address the progress happening in the recognition, diagnosis and treatment of the disease. Host Matt Gee, Director of Collaborations and External Engagement at Siemens Healthineers, is joined by Dr. Michelle Long, International Medical Vice President of Metabolic Dysfunction-Associated Steatohepatitis at Novo Nordisk and Director of Clinical Research for the Section of Gastroenterology and Hepatology at Boston University; Dr. Arun Sanyal, Professor of Medicine, Physiology, and Molecular Pathology in the Division of Gastroenterology at Virginia Commonwealth University; and Michael Betel, President and Founder of the Fatty Liver Alliance.What you'll learn in this episode:One of the biggest obstacles to diagnosing MASLD before it progresses stems from the lack of visibility and awareness of the diseaseMASLD is a reversible disease when caught in timeMASLD is more complex than a patient's diet or lifestyle—metabolic dysfunction plays a role Non-invasive testing has become an important tool in advancing patient careConnect with Matt GeeLinkedIn Connect with Michelle LongLinkedInConnect with Arun SanyalVCU.eduConnect with Michael BetelLinkedIn Hosted on Acast. See acast.com/privacy for more information.

Dr. Hoffman continues his conversation with Dr. Garth Nicolson, Founder, President, Chief Scientific Officer, and Emeritus Research Professor of Molecular Pathology at the Institute for Molecular Medicine in Huntington Beach, California, and Research Advisor for Nutritional Therapeutics, makers of NTFactor.

Equitable biomarker testing access, including pharmacogenomics testing, is critical for patients to experience optimal medication therapy outcomes. Be sure to tune in to this episode of the Precision Health and PGX Podcast as Dr. Becky Winslow, Dr. Behnaz Sarrami, and Hilary Goeckner, Director of State & Local Campaigns - Access to Care of the American Cancer Society Cancer Action Network (ACS CAN), educate listeners about ACS CAN's mission, how it executes on its mission, accomplishments, and future goals.  This episode is a must listen for anyone who wants the latest update on the American Cancer Society Cancer Action Network's work influencing state legislatures to pass legislation to expand coverage of biomarker testing, states who have already passed legislation and those with pending legislation, and to learn how they too can advocate.   After listening to this episode, listeners will be able to describe biomarker testing's importance in healthcare; describe how the American Cancer Society Cancer Action Network is championing biomarker testing coverage legislation; name states that have passed biomarker testing legislation and those with pending legislation; know how one can contribute to the efforts to increase biomarker testing coverage. Hilary Gee Goeckner is director of state and local campaigns for the American Cancer Society Cancer Action Network (ACS CAN), the advocacy affiliate of the American Cancer Society. In this role she leads work with ACS CAN staff and coalition partners across the country to improve access to comprehensive biomarker testing, clinical trials, fertility preservation and other health care access issues. Prior to this role, Hilary served as the Kansas government relations director for ACS CAN. Before joining ACS CAN, Hilary served as director of health policy at Kansas Action for Children. She holds a bachelor's degree in anthropology and global health from Williams College and a master's degree in social work from Boston College. She lives in San Diego with her husband and two children. As the CEO of inGENEious RX Incorporated and pharmacogenomics subject matter expert, Dr. Becky Winslow has dedicated over a decade to providing innovative solutions for pharmacogenomics stakeholders. Her extensive experience also includes directing pharmacy operations and medication safety programs across diverse clinical settings, spanning retail, hospital, long-term care, and public health. Dr. Winslow is a passionate educator, training Doctors of Clinical Pharmacy to work with molecular testing stakeholders and serving as an advanced pharmacy practice preceptor for Manchester University's Master of Science in Pharmacogenomics Program. She hosts an evidence-based educational podcast, The Precision Health and PGx Podcast, which Welp Magazine recognized as the ninth most listened to genetics podcast globally. Her involvement with prominent organizations like the Clinical Pharmacogenetics Implementation Consortium and the National Council for Prescription Drug Programs (NCPDP) PGx Task Force speaks to her expertise and commitment. Dr. Winslow frequently presents at national conferences such as The Association for Molecular Pathology and holds degrees from Campbell University.  Behnaz Sarrami, PharmD, MS, is a leading expert in pharmacogenomics and a dedicated Medical Science Liaison (MSL). She is named American Pharmacists Association's (APhA) "50 Most Influential Leaders in Pharmacy" and Medika's "Top 30 Women Transforming Healthcare". Behnaz is passionate about advancing personalized medicine to optimize treatments and improve patient outcomes, especially in underserved populations. She supports healthcare professionals through scientific training and presentations. As the host of the "Precision Health and PGx" podcast, she mentors pharmacists transitioning into MSL roles and those launching pharmacogenomics consulting careers. She earned her Master's in Biochemistry from Georgetown University and her Doctorate in Pharmacy from Creighton University. With significant contributions to research and education, she continues to drive innovation in pharmacogenomics through her work with healthcare professionals and community outreach programs.  

Equitable biomarker testing access, including pharmacogenomics testing, is critical for patients to experience optimal medication therapy outcomes. Be sure to tune in to this episode of the Precision Health and PGX Podcast as Dr. Becky Winslow, Dr. Behnaz Sarrami, and Hilary Goeckner, Director of State & Local Campaigns - Access to Care of the American Cancer Society Cancer Action Network (ACS CAN), educate listeners about ACS CAN's mission, how it executes on its mission, accomplishments, and future goals.  This episode is a must listen for anyone who wants the latest update on the American Cancer Society Cancer Action Network's work influencing state legislatures to pass legislation to expand coverage of biomarker testing, states who have already passed legislation and those with pending legislation, and to learn how they too can advocate.   After listening to this episode, listeners will be able to describe biomarker testing's importance in healthcare; describe how the American Cancer Society Cancer Action Network is championing biomarker testing coverage legislation; name states that have passed biomarker testing legislation and those with pending legislation; know how one can contribute to the efforts to increase biomarker testing coverage. Hilary Gee Goeckner is director of state and local campaigns for the American Cancer Society Cancer Action Network (ACS CAN), the advocacy affiliate of the American Cancer Society. In this role she leads work with ACS CAN staff and coalition partners across the country to improve access to comprehensive biomarker testing, clinical trials, fertility preservation and other health care access issues. Prior to this role, Hilary served as the Kansas government relations director for ACS CAN. Before joining ACS CAN, Hilary served as director of health policy at Kansas Action for Children. She holds a bachelor's degree in anthropology and global health from Williams College and a master's degree in social work from Boston College. She lives in San Diego with her husband and two children. As the CEO of inGENEious RX Incorporated and pharmacogenomics subject matter expert, Dr. Becky Winslow has dedicated over a decade to providing innovative solutions for pharmacogenomics stakeholders. Her extensive experience also includes directing pharmacy operations and medication safety programs across diverse clinical settings, spanning retail, hospital, long-term care, and public health. Dr. Winslow is a passionate educator, training Doctors of Clinical Pharmacy to work with molecular testing stakeholders and serving as an advanced pharmacy practice preceptor for Manchester University's Master of Science in Pharmacogenomics Program. She hosts an evidence-based educational podcast, The Precision Health and PGx Podcast, which Welp Magazine recognized as the ninth most listened to genetics podcast globally. Her involvement with prominent organizations like the Clinical Pharmacogenetics Implementation Consortium and the National Council for Prescription Drug Programs (NCPDP) PGx Task Force speaks to her expertise and commitment. Dr. Winslow frequently presents at national conferences such as The Association for Molecular Pathology and holds degrees from Campbell University.  Behnaz Sarrami, PharmD, MS, is a leading expert in pharmacogenomics and a dedicated Medical Science Liaison (MSL). She is named American Pharmacists Association's (APhA) "50 Most Influential Leaders in Pharmacy" and Medika's "Top 30 Women Transforming Healthcare". Behnaz is passionate about advancing personalized medicine to optimize treatments and improve patient outcomes, especially in underserved populations. She supports healthcare professionals through scientific training and presentations. As the host of the "Precision Health and PGx" podcast, she mentors pharmacists transitioning into MSL roles and those launching pharmacogenomics consulting careers. She earned her Master's in Biochemistry from Georgetown University and her Doctorate in Pharmacy from Creighton University. With significant contributions to research and education, she continues to drive innovation in pharmacogenomics through her work with healthcare professionals and community outreach programs.  

Be sure to tune in to this episode of the Precision Health and PGX Podcast as Dr. Becky Winslow, Dr. Behnaz Sarrami, and Dr. Jeremy Stuart, Chief Scientific Officer and laboratory director for Precision Genetics, discuss pharmacists value as employees in clinical pharmacogenomics testing laboratories. Having employed pharmacists in his laboratories, Dr. Stuart will provide his first-hand examples to illustrate how pharmacists have benefited his laboratories. Dr. Winslow and Dr. Sarrami will also share their real-world experiences working for clinical pharmacogenomics laboratories to help the laboratory achieve its goals. This episode is a must listen for laboratories who are vested in their pharmacogenomics testing's financial success.  After listening to this episode, the learner will be able to describe responsibilities and roles in pharmacogenomics pharmacists fulfill in clinical labs, name specific real-world examples that illustrate pharmacists' contributions to pharmacogenomics in the clinical laboratory, and name education, training, and work experiences that prepare pharmacists to assume advanced practice roles in clinical laboratories.   Dr. Jeremy Stuart has extensive experience in the life science industry. He specializes in commercial operations, technology development and transfer, manufacturing design, and validation of laboratory developed tests (LDTs). He currently serves as the Chief Scientific Officer for Precision Genetics and serves as their Laboratory Director.  Dr. Stuart was part of the senior management team that completed a management buyout of Lab21 Inc. to form Selah Genomics and the subsequent sale of Selah to EKF. Dr. Stuart led the development and validation of all of Selah's molecular assays and oversaw their clinical studies. Dr. Stuart was also a member of the Agencourt Personal Genomics team, where he co-developed the SOLiD next-generation sequencing technology that was subsequently acquired by Applied Biosystems.   Before entering industry, Dr. Stuart completed his postdoctoral work at the the Harvard School of Public Health, earned his master's degree in Toxicology from the University of Minnesota, and his doctorate in Genetics & Complex Diseases from Harvard University.  As the CEO of inGENEious RX Incorporated and pharmacogenomics subject matter expert, Dr. Becky Winslow has dedicated over a decade to providing innovative solutions for pharmacogenomics stakeholders. Her extensive experience also includes directing pharmacy operations and medication safety programs across diverse clinical settings, spanning retail, hospital, long-term care, and public health. Dr. Winslow is a passionate educator, training Doctors of Clinical Pharmacy to work with molecular testing stakeholders and serving as an advanced pharmacy practice preceptor for Manchester University's Master of Science in Pharmacogenomics Program. She hosts an evidence-based educational podcast, The Precision Health and PGx Podcast, which Welp Magazine recognized as the ninth most listened to genetics podcast globally. Her involvement with prominent organizations like the Clinical Pharmacogenetics Implementation Consortium and the National Council for Prescription Drug Programs (NCPDP) PGx Task Force speaks to her expertise and commitment. Dr. Winslow frequently presents at national conferences such as The Association for Molecular Pathology and holds degrees from Campbell University.  Behnaz Sarrami, PharmD, MS, is a leading expert in pharmacogenomics and a dedicated Medical Science Liaison (MSL). She is named American Pharmacists Association's (APhA) "50 Most Influential Leaders in Pharmacy" and Medika's "Top 30 Women Transforming Healthcare". Behnaz is passionate about advancing personalized medicine to optimize treatments and improve patient outcomes, especially in underserved populations. She supports healthcare professionals through scientific training and presentations. As the host of the "Precision Health and PGx" podcast, she mentors pharmacists transitioning into MSL roles and those launching pharmacogenomics consulting careers. She earned her Master's in Biochemistry from Georgetown University and her Doctorate in Pharmacy from Creighton University. With significant contributions to research and education, she continues to drive innovation in pharmacogenomics through her work with healthcare professionals and community outreach programs.

Be sure to tune in to this episode of the Precision Health and PGX Podcast as Dr. Becky Winslow, Dr. Behnaz Sarrami, and Dr. Jeremy Stuart, Chief Scientific Officer and laboratory director for Precision Genetics, discuss pharmacists value as employees in clinical pharmacogenomics testing laboratories. Having employed pharmacists in his laboratories, Dr. Stuart will provide his first-hand examples to illustrate how pharmacists have benefited his laboratories. Dr. Winslow and Dr. Sarrami will also share their real-world experiences working for clinical pharmacogenomics laboratories to help the laboratory achieve its goals. This episode is a must listen for laboratories who are vested in their pharmacogenomics testing's financial success.  After listening to this episode, the learner will be able to describe responsibilities and roles in pharmacogenomics pharmacists fulfill in clinical labs, name specific real-world examples that illustrate pharmacists' contributions to pharmacogenomics in the clinical laboratory, and name education, training, and work experiences that prepare pharmacists to assume advanced practice roles in clinical laboratories.   Dr. Jeremy Stuart has extensive experience in the life science industry. He specializes in commercial operations, technology development and transfer, manufacturing design, and validation of laboratory developed tests (LDTs). He currently serves as the Chief Scientific Officer for Precision Genetics and serves as their Laboratory Director.  Dr. Stuart was part of the senior management team that completed a management buyout of Lab21 Inc. to form Selah Genomics and the subsequent sale of Selah to EKF. Dr. Stuart led the development and validation of all of Selah's molecular assays and oversaw their clinical studies. Dr. Stuart was also a member of the Agencourt Personal Genomics team, where he co-developed the SOLiD next-generation sequencing technology that was subsequently acquired by Applied Biosystems.   Before entering industry, Dr. Stuart completed his postdoctoral work at the the Harvard School of Public Health, earned his master's degree in Toxicology from the University of Minnesota, and his doctorate in Genetics & Complex Diseases from Harvard University.  As the CEO of inGENEious RX Incorporated and pharmacogenomics subject matter expert, Dr. Becky Winslow has dedicated over a decade to providing innovative solutions for pharmacogenomics stakeholders. Her extensive experience also includes directing pharmacy operations and medication safety programs across diverse clinical settings, spanning retail, hospital, long-term care, and public health. Dr. Winslow is a passionate educator, training Doctors of Clinical Pharmacy to work with molecular testing stakeholders and serving as an advanced pharmacy practice preceptor for Manchester University's Master of Science in Pharmacogenomics Program. She hosts an evidence-based educational podcast, The Precision Health and PGx Podcast, which Welp Magazine recognized as the ninth most listened to genetics podcast globally. Her involvement with prominent organizations like the Clinical Pharmacogenetics Implementation Consortium and the National Council for Prescription Drug Programs (NCPDP) PGx Task Force speaks to her expertise and commitment. Dr. Winslow frequently presents at national conferences such as The Association for Molecular Pathology and holds degrees from Campbell University.  Behnaz Sarrami, PharmD, MS, is a leading expert in pharmacogenomics and a dedicated Medical Science Liaison (MSL). She is named American Pharmacists Association's (APhA) "50 Most Influential Leaders in Pharmacy" and Medika's "Top 30 Women Transforming Healthcare". Behnaz is passionate about advancing personalized medicine to optimize treatments and improve patient outcomes, especially in underserved populations. She supports healthcare professionals through scientific training and presentations. As the host of the "Precision Health and PGx" podcast, she mentors pharmacists transitioning into MSL roles and those launching pharmacogenomics consulting careers. She earned her Master's in Biochemistry from Georgetown University and her Doctorate in Pharmacy from Creighton University. With significant contributions to research and education, she continues to drive innovation in pharmacogenomics through her work with healthcare professionals and community outreach programs.

Before founding inGENEious RX Incorporated, a boutique pharmacogenomics consulting firm, Dr. Winslow directed pharmacy business operations and clinical pharmacy programs in retail, hospital, long-term care, and public health pharmacies for Walmart Stores, Community Health Systems, Neil Medical Group, and the North Carolina Department of Health and Human Services. Since founding inGENEious RX over eleven years ago, Dr. Winslow has worked with numerous distinguished vendors in the pharmacogenomics industry including Translational Software, Admera Health, Genemarkers, National Association of Chain Drug Stores, Kentucky Teachers' Retirement System, GenXys, and Thermo Fisher Scientific.  A sought-after pharmacogenomics subject matter expert, Dr. Winslow, has authored PGx payer databases and billing and coding algorithms and served Mintz Law as the expert medical necessity reviewer of Medicare PGx claims. She is an authority in pharmacogenomics access and reimbursement and specializes in business strategy consulting for pharmacogenomics stakeholders.   Dr. Winslow is an Advanced Pharmacy Practice Experience preceptor for Manchester University School of Pharmacy PharmD/Masters in PGx students and a registered trainer for the University of Pittsburgh's Test2Learn (TM) Community PGx Certificate Program. Dr. Winslow is a member of the Clinical Pharmacogenetics Implementation Consortium, the NCPDP PGx Task Force, and the Get the Medications Right Institute.  In 2021, Welp Magazine recognized Dr. Winslow's podcast, the PGx for Pharmacists Podcast, as the world's ninth most listened-to genetics podcast. Her podcast shares the top 20 most listened-to genomics podcast list with genomics podcasts created by such notable podcasters as the National Cancer Institute and the American Heart Association. The Pharmacy Podcast Network recognized Dr. Winslow in 2021 as a Top 50 pharmacy influencer. Entities frequently recruit Dr. Winslow to present PGx topics. She has presented at conferences for the National Association of Boards of Pharmacy, the National Association of Specialty Pharmacy, the Inovalon Customer Congress, and the Association for Molecular Pathology and on the Labroots' and Precision Medicine Institute's platforms.  Dr. Winslow earned her Bachelor of Science in Biology and Doctor of Clinical Pharmacy degrees from Campbell University. Lexi Wensel is a 2024 Manchester University School of Pharmacy graduate where she earned her Doctorate in Pharmacy and Masters in Pharmacogenomics. When this episode was recorded in April 2024, Lexi was completing an advanced pharmacy practice experience with Dr. Becky Winslow, preceptor for Manchester University School of Pharmacy. While studying to become a pharmacist, Lexi gained practical clinical pharmacy experience while working as a pharmacy intern at both Meijer pharmacy and Marion Health Hospital.   Beyond her academic and professional endeavors, Lexi is deeply committed to giving back to the community. She serves as a board member for an organization called Guatemala Family Development where she contributed to initiatives aimed at improving healthcare access and promoting wellness in underserved communities. At the time this episode was recorded, Lexi was completing an advanced pharmacy practice experience with Dr. Becky Winslow, preceptor for Manchester University School of Pharmacy.  Dr. Mary Weissman is a clinical pharmacogenomics specialist and inGENEious RX Incorporated consultant. Since earning her Doctor of Pharmacy degree from Arnold and Marie Schwartz College of Pharmacy and completing a two-year pharmacogenomics fellowship in a clinical laboratory's medical affairs department, Dr. Weissman has applied her pharmacogenomics expertise in clinical diagnostic laboratories. At those laboratories, she has scientifically, and clinically supported pharmacogenomics stakeholders to increase clinical pharmacogenomics implementation into clinical settings. Holding titles such as clinical scientist, she has authored and developed medical content to educate healthcare providers and patients about pharmacogenomics and authored clinical decision support tools prescribers use to leverage pharmacogenomic insights in medication therapy management. Through educational trainings, white papers, presentations, and webinars, she has clarified pharmacogenomics' complexities and helped move pharmacogenomics toward a standard of care.  

Before founding inGENEious RX Incorporated, a boutique pharmacogenomics consulting firm, Dr. Winslow directed pharmacy business operations and clinical pharmacy programs in retail, hospital, long-term care, and public health pharmacies for Walmart Stores, Community Health Systems, Neil Medical Group, and the North Carolina Department of Health and Human Services. Since founding inGENEious RX over eleven years ago, Dr. Winslow has worked with numerous distinguished vendors in the pharmacogenomics industry including Translational Software, Admera Health, Genemarkers, National Association of Chain Drug Stores, Kentucky Teachers' Retirement System, GenXys, and Thermo Fisher Scientific.  A sought-after pharmacogenomics subject matter expert, Dr. Winslow, has authored PGx payer databases and billing and coding algorithms and served Mintz Law as the expert medical necessity reviewer of Medicare PGx claims. She is an authority in pharmacogenomics access and reimbursement and specializes in business strategy consulting for pharmacogenomics stakeholders.   Dr. Winslow is an Advanced Pharmacy Practice Experience preceptor for Manchester University School of Pharmacy PharmD/Masters in PGx students and a registered trainer for the University of Pittsburgh's Test2Learn (TM) Community PGx Certificate Program. Dr. Winslow is a member of the Clinical Pharmacogenetics Implementation Consortium, the NCPDP PGx Task Force, and the Get the Medications Right Institute.  In 2021, Welp Magazine recognized Dr. Winslow's podcast, the PGx for Pharmacists Podcast, as the world's ninth most listened-to genetics podcast. Her podcast shares the top 20 most listened-to genomics podcast list with genomics podcasts created by such notable podcasters as the National Cancer Institute and the American Heart Association. The Pharmacy Podcast Network recognized Dr. Winslow in 2021 as a Top 50 pharmacy influencer. Entities frequently recruit Dr. Winslow to present PGx topics. She has presented at conferences for the National Association of Boards of Pharmacy, the National Association of Specialty Pharmacy, the Inovalon Customer Congress, and the Association for Molecular Pathology and on the Labroots' and Precision Medicine Institute's platforms.  Dr. Winslow earned her Bachelor of Science in Biology and Doctor of Clinical Pharmacy degrees from Campbell University. Lexi Wensel is a 2024 Manchester University School of Pharmacy graduate where she earned her Doctorate in Pharmacy and Masters in Pharmacogenomics. When this episode was recorded in April 2024, Lexi was completing an advanced pharmacy practice experience with Dr. Becky Winslow, preceptor for Manchester University School of Pharmacy. While studying to become a pharmacist, Lexi gained practical clinical pharmacy experience while working as a pharmacy intern at both Meijer pharmacy and Marion Health Hospital.   Beyond her academic and professional endeavors, Lexi is deeply committed to giving back to the community. She serves as a board member for an organization called Guatemala Family Development where she contributed to initiatives aimed at improving healthcare access and promoting wellness in underserved communities. At the time this episode was recorded, Lexi was completing an advanced pharmacy practice experience with Dr. Becky Winslow, preceptor for Manchester University School of Pharmacy.  Dr. Mary Weissman is a clinical pharmacogenomics specialist and inGENEious RX Incorporated consultant. Since earning her Doctor of Pharmacy degree from Arnold and Marie Schwartz College of Pharmacy and completing a two-year pharmacogenomics fellowship in a clinical laboratory's medical affairs department, Dr. Weissman has applied her pharmacogenomics expertise in clinical diagnostic laboratories. At those laboratories, she has scientifically, and clinically supported pharmacogenomics stakeholders to increase clinical pharmacogenomics implementation into clinical settings. Holding titles such as clinical scientist, she has authored and developed medical content to educate healthcare providers and patients about pharmacogenomics and authored clinical decision support tools prescribers use to leverage pharmacogenomic insights in medication therapy management. Through educational trainings, white papers, presentations, and webinars, she has clarified pharmacogenomics' complexities and helped move pharmacogenomics toward a standard of care.  

Saeed Khan, Ph.D., Head of the Department of Molecular Pathology at Dow diagnostic research and reference laboratory and President of the Pakistan Biological Safety Association discusses the importance and challenges of biosafety/biosecurity practices on both a local and global scale. He highlights key steps for biorisk assessment and management and stresses the importance of training, timing and technology. Ashley's Biggest Takeaways Adequate biosafety and biosecurity protocols depend on a thorough understanding of modern challenges, and scientists must be willing and able to respond to new technological threats appropriately. In the microbiology lab, the threat goes beyond the physical pathogen. Implications of genomics and cyber security must be built into biorisk management techniques, including data storage and waste management practices. Risk assessments involve evaluation of both inherent and residual risk. Inherent risk is linked to the pathogen. Residual risk varies according to the lab, equipment, employee, environment, etc. As a result, biosafety and biosecurity risks are constantly changing, and assessments must be repeated strategically and often. Khan recommended repeating a risk assessment whenever a key variable in the equation changes, i.e., new equipment, new employee, new pathogen. He also recommended (at minimum) conducting routine risk assessments every 6 months, or twice a year. Featured Quotes:  “We need to have basic biosafety and biosecurity to stay away from these bugs and the modern challenges, like cyber biosecurity and genomics. These are the new areas, which are potential threats for the future, and where we need to train our researchers and students.” “Starting from simple hand washing or hand hygiene, the basic things we use are gloves, goggles and PPE to protect the workers, the staff and the patient from getting infected from the environment, laboratory or hospitals. These are the basic things, and it's very crucial, because if one is not using gloves in the lab or not wearing the lab coat, he or she may get infected from the sample, and the patient can get infected from the physician and doctors or nurse if they are not following the basic biosafety rules. These [things] are routinely important. Every day we should practice this.” “But there are [also] new challenges. Particularly in the microbiology lab, we [used to] think that once we killed the bacteria, then it's fine. But nowadays, it's not the way we should think about it. Though you kill the bacteria practically, it still has a sequence, [which] we call the genome, and if you have that information with you, you theoretically have the potential to recreate that pathogen… that can be used or maybe misused as well.” “[Working with] scripts of pathogens, like smallpox or the polioviruses, we call this synthetic biology. Different scientists are doing it for the right purposes, like for production of vaccines, to find new therapeutics, to understand the pathology of the diseases. But on [the other hand]—we call it dual use research of concern (DURC)—the same can be misused as well. That's why it's very important to be aware of the bugs that we are working with, and the potential of that pathogen or microbe, to the extent that can be useful or otherwise.” “So, we should be aware of the new concern of the technology, synthetic biology and DURC. These are new concepts—cyber, biosecurity and information security [are all] very much important these days. You cannot be relaxed being in the microbiology lab. Once we have identified a pathogen, declared a result to the patient and the physician, and it's been treated, we [still] need to be worried about waste management—that we discard that waste properly and we have proper inventory control of our culture. It should be safe in the locker or on in the freezers and properly locked, so we should not be losing any single tube of the culture, otherwise it may be misused.” Risk Assessment “The best word that you have used is risk assessment. So, it should gage the severity of the issue. We should not over exaggerate the risk, and we should not undermine the risk. Once the risk assessment been made, we can proceed.” “Right from the beginning of touching a patient or a sample of the patient until the end of discarding the sample, that is called biorisk management. It's a complete science that we need to be aware of—not in bits and pieces. Rather a comprehensive approach should be adopted, and each and every person in the organization should be involved. Otherwise, we may think [we are] doing something good, but someone else may spoil the whole thing, and it will be counterproductive at the end.” “We should involve each and every person working with us and the lab, and we should empower them. They should feel ownership that they are working with us, and they are [as] responsible as we are. So, this the whole process needs to be properly engaged. People must be engaged, and they should be empowered, and they should be responsible.” “Each and every lab has different weaknesses and strengths of their own, which play an important role in the risk assessment.” “There is inherent risk, which is linked with the pathogen, and there is another thing we call residual risk. So, residual risk everywhere and varies. Though the inherent risk may be the same, the residual risk is based on the training of the person, the lab facility that is available, the resources that labs have and the potential threats from the environment.” “It's not usually possible that you do a risk assessment every day. So, when you have different factors involving a new pathogen in your lab, you have new equipment in your in your lab, or some new employee in your lab—[a new] variable factor that is involved—you should [perform] the risk assessment. Otherwise, [a routine risk assessment] should [be done] twice a year, after 6 months.” “Training is important, and response time is very much crucial. And different technology plays a vital role, but the lack of technology should not be an excuse for not responding. There is always an alternative on the ground that you may do the risk assessment. And within the given resources and facility, we should mimic the technology and respond to any outbreaks or disease within our given resources.” Links for the Episode ASM Guidelines for Biosafety in Teaching Laboratories Pakistan Biological Safety Association Training to be a Biosafety Professional (video) Take the MTM listener survey!

Francisco X. Real, MD, PhDNational Cancer Research CenterMadrid, SpainThe therapeutic landscape for urothelial cancer has undergone significant transformation in recent years, with the addition of PD1/PD-L1 targeting immune checkpoint inhibitors and novel targeted therapies and antibody-drug conjugates (ADCs) adding to the complexity of treatment options available for patients throughout the course of their disease. The optimal sequencing of treatments depends on an understanding of the relevance of different pathological subtypes of the disease and of the latest clinical evidence and guidelines that support the use of different therapies. These considerations were discussed in detail during the recent ‘Urothelial Cancer Preceptorship', in which experts in the field provided a detailed grounding of the disease process and management from diagnosis through to salvage treatments of advanced disease.View the Expert Interview on Specialist Insights in Urothelial Cancer from each faculty member which features specific expert insights on the topics related to the faculty presentations and the key questions discussed during the preceptorship. The enduring materials aimed to enable clinicians to integrate the latest advances and use of novel therapies for advanced urothelial cancer into safe and effective patient care. The presentation slides of the Preceptorship are also available to download.Based on the Expert Interview of Specialist Insights and Preceptorship held on 18 and 19 September 2024.

References Acta Physiologica (Oxford)2024. V.240, Issue 3 e14107 Int. J. Mol. Sci. 2023, 24, 5564 Simon, Paul and Bruce Woodley. 1966.The Cyrkle. "Red Rubber Ball" https://open.spotify.com/track/6DuLN8tFW0DkH9wsbTHZsX?si=3bc8b99f3ae34ac6 Robert Fripp, Ian McDonald, Greg Lake, Michael Giles, Pete Sinfield English 1969. "Court of the Crimson King" King Crimson https://open.spotify.com/track/3kzbkZtBqamTgyO31DO1Sn?si=ff8d5fd6194740d6 Mendelsshon. F. 1830. Overture:"The Hebrides/ Fingal's Cave" Op. 26. https://open.spotify.com/track/5u04CcLiM8zflXQIPcyprv?si=2b08f07ddbe34ed0 --- Support this podcast: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/support

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Medtronic's chief medical officer of acute care and monitoring has departed for a new role. The FDA has finalized voluntary malfunction summary reporting guidance. Penumbra is laying off 71 people after axing its virtual reality division. Qiagen and AstraZeneca have expanded their companion diagnostic pact. The Association for Molecular Pathology is suing to block an FDA lab test rule. Layoffs in the medical device industry continue to be a trend. Industry news includes the launch of the first over-the-counter glucose monitor, unexpected partnerships in diabetes tech, and pushback on FDA regulation of lab-developed tests.The text discusses various updates in the biopharma industry, including Alnylam's heart drug data sparking debate, Novo building a heart failure case for semaglutide, and a slump in cell and gene therapy investment. The industry is shifting towards more patient-centric commercialization strategies, with companies like Pfizer and Lilly breaking into the direct-to-consumer market. The summer has been a mixed bag for biotech, with market fluctuations and limited IPOs and acquisitions. Alnylam's full study data on its heart drug vutrisiran showed benefits but also raised skepticism. Novo's analysis showed semaglutide's effectiveness in reducing heart failure risk. Additionally, PBM executives are facing fines for alleged perjury in a house hearing defending their business practices.The text discusses the pricing and sales of gene therapies, particularly focusing on Novartis' Zolgensma, which has been the only gene therapy to cross the blockbuster threshold with sales of $1.2 billion in 2021 and $1.4 billion in 2022. While high price tags have not always resulted in significant returns for pharmaceutical companies with gene therapies, Zolgensma has been an exception. Other companies have faced challenges with new gene therapies, such as Biomarin Pharmaceuticals, which recently announced layoffs due to dismal sales of its hemophilia A gene therapy Roctavian.Alnylam Pharmaceuticals has released detailed data on their drug Vutrisiran, showing its benefits in treating a progressive and fatal heart condition known as ATTR cardiomyopathy. The results were published in the New England Journal of Medicine. While the data confirms the therapy's benefit, there are still questions about how exactly Vutrisiran should be used in treating the disease. The study is expected to continue to fuel debate among doctors.The text discusses the recent slump in investment in cell and gene therapy, with fewer venture funding rounds closed by developers in the first six months of 2024. Two companies, Biomarin and Tome Biosciences, are cutting jobs, with over 200 and over 100 layoffs respectively. Biomarin has made changes to its executive team and drug pipeline to refocus resources. Additionally, Bayer has partnered with RNA drugmaker Nextrna Therapeutics to develop new cancer therapies. The text also highlights the challenges faced in clinical trials, with nearly 80% failing to meet enrollment goals and schedules. The importance of understanding social determinants of health for research is emphasized.Biopharma Dive's Gene Therapy Weekly provides news and insights on gene therapy for biopharma leaders.

Catarina Eloy MD, PhD is a pathologist and Director of The Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP). She joins BTS to discuss the transformation of IPATIMUP to a fully integrated digital pathology laboratory and how new technology is improving diagnostic efficiency and patient treatment outcomes in Portugal. Additional topics include AI initiatives for pathology and advice on how to get started going digital.A forum to engage with the hosts and other listeners has been launched on the DPA website www.digitalpathologyassociation.org. DPA members may login to the DPA Collaborate hub (under the Resources tab) and join the Beyond The Scope community. All listeners are encouraged to use this forum to suggest future topics and guests, submit questions and corrections, and provide general feedback.

Guests include Gina Sanchez to talk about her paper, “Status of abortion curriculum in genetic counseling: Survey of graduate programs and recent graduates in the United States” and Dr. Holly Rankin to discuss her paper, “Termination counseling among US perinatal genetic counselors in the setting of second trimester fetal anomalies.”   Segment 1: Gina Sanchez, MS, MB(ASCP), CGC is a genetic counselor and Instructor in the Department of Obstetrics, Gynecology, and Reproductive Sciences at the McGovern Medical School at The University of Texas Health Science Center at Houston. She received a BS in Zoology from Texas Tech University in 2012, a MS in Molecular Pathology from Texas Tech University Health Sciences Center in 2013, and a MS in Genetic Counseling from The University of Texas Genetic Counseling Program in 2022. Gina provides prenatal genetic counseling services in both English and Spanish at several Houston area clinics. She is a member of the National Society of Genetic Counselors and the Texas Society of Genetic Counselors. Gina's research interests include genetic counseling education and increasing access to genetic counseling care for the Spanish-speaking patient population. In this segment, we discuss: Assessment of the abortion curriculum in genetic counseling graduate programs and the study participants. Variability in the amount and types of abortion training across surveyed programs. Factors influencing the training provided. Greater satisfaction and preparedness among graduates from programs with a dedicated abortion curriculum. Notable discrepancies between responses from recent graduates and program representatives. Key topics highlighted as important parts of abortion education. Variability in clinical training as a barrier to abortion education and potential solutions to standardize this education. Segment 2: Dr. Holly Rankin received her undergraduate degree in anthropology, graduating summa cum laude, from the University of California, Los Angeles. She completed her medical education at Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia where she was inducted into the Gold Humanism and the Alpha Omega Alpha Honor Societies. Dr. Rankin completed her residency training in Obstetrics and Gynecology at Johns Hopkins University, Baltimore. She received the Ryan Program Excellence in Family Planning Award at the end of residency training. Dr. Rankin is excited to be a Complex Family Planning fellow at UC Davis and plans to focus her career on providing abortion and contraceptive specialty care to underserved, rural communities. In this segment, we discuss: The impact of state laws and location on counseling and termination options. Differences between genetic counselors and other healthcare providers in handling these cases. Balancing patient autonomy with counseling challenges. How reproductive justice affects the discussion of termination options, especially with changing abortion laws.   Follow us on Instagram @dnadialoguespodcast and on LinkedIn at Journal of Genetic Counseling.   Stay tuned for the next new episode of DNA Dialogues! In the meantime, listen to all our episodes Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “DNA Dialogues”.    For more information about this episode visit dnadialogues.podbean.com, where you can also stream all episodes of the show. Check out the Journal of Genetic Counseling here for articles featured in this episode and others.    Any questions, episode ideas, guest pitches, or comments can be sent into DNADialoguesPodcast@gmail.com.    DNA Dialogues' team includes Jehannine Austin, Naomi Wagner, Khalida Liaquat, Kate Wilson and DNA Today's Kira Dineen. Our logo was designed by Ashlyn Enokian. Our current intern is Sydney Arlen.  

IP in the Digital Environment Software and Digital Media Copyright Protection: Software and digital media are primarily protected under copyright law. Software Licensing: Various licensing models, such as open-source and proprietary licenses, dictate how software can be used, modified, and distributed. Digital Rights Management (DRM): Technologies designed to prevent unauthorized copying and use of digital media. Legal Considerations Infringement and Enforcement: Identifying and prosecuting copyright infringement in the digital realm is complex due to the global nature of the internet and the anonymity it can provide. Fair Use and Exceptions: Balancing the rights of IP holders with those of users, particularly in contexts like education and research, where fair use exceptions might apply. Case Law Oracle America, Inc. v. Google LLC: A landmark case addressing whether the use of Java APIs in Android constitutes fair use. Biotechnology and Genetic Engineering Key Issues Patenting Life Forms: The extent to which living organisms, genetic sequences, and biotechnological inventions can be patented. Ethical and Moral Considerations: Balancing IP protection with ethical concerns, such as the impact on biodiversity, human rights, and public health. Legal Considerations Patent Eligibility: Determining what constitutes patentable subject matter in biotechnology, including genetically modified organisms (GMOs), gene editing technologies like CRISPR, and synthetic biology. Regulatory Compliance: Navigating the complex regulatory frameworks that govern biotechnology, which can vary significantly between jurisdictions. Case Law Diamond v. Chakrabarty: A seminal Supreme Court case that allowed for the patenting of a genetically modified bacterium, establishing that living organisms could be patented if they are the product of human ingenuity. Association for Molecular Pathology v. Myriad Genetics, Inc.: Addressed whether human genes could be patented. Artificial Intelligence and IP Key Issues Authorship and Ownership: Determining who owns the IP rights to creations generated by AI, such as artwork, music, or inventions. Patentability of AI Innovations: Assessing whether AI-generated inventions meet the criteria for patent protection, including inventiveness and non-obviousness. Legal Considerations AI as an Inventor: Current IP laws generally require a human inventor. The question of whether AI can be recognized as an inventor is hotly debated. Data and Training Sets: Protecting the data used to train AI systems, which often involves large datasets that may include copyrighted material. Case Law Thaler v. Commissioner of Patents: A case in which the Federal Court of Australia ruled that AI could be listed as an inventor on a patent application. Future Trends and Legislative Changes Key Trends Harmonization of IP Laws: Efforts to harmonize IP laws across jurisdictions to facilitate global trade and reduce complexity for multinational companies. Digital Transformation: Adapting IP laws to better protect digital assets and address issues like cyber piracy and the protection of digital identities. Legislative Changes Copyright Modernization: Updating copyright laws to better reflect the realities of the digital age, such as shorter terms of protection for digital works or more flexible fair use provisions. Patent Law Reforms: Revisiting patent eligibility criteria, particularly in fields like biotechnology and AI, to encourage innovation while balancing public interest. Case Law and Policy Developments European Union's Digital Single Market Directive: Aims to modernize copyright rules to facilitate digital trade within the EU. US Patent and Trademark Office (USPTO) AI Initiative: Exploring how AI impacts patent law, including the potential need for legislative changes to accommodate AI-generated inventions --- Send in a voice message: https://podcasters.spotify.com/pod/show/law-school/message Support this podcast: https://podcasters.spotify.com/pod/show/law-school/support

Last month, Catherine, Princess of Wales shared she'd been diagnosed with cancer. Describing this news as ‘a huge shock' and at age just 42, the Princess' disease falls into a category known as “early-onset cancer” – when the disease affects those under 50. While cases in this age group are still rare, diagnosis rates over the past few years have been growing. And scientists are now on a mission to figure out why. Receiving a cancer diagnosis at any age is devastating, but younger people living with the disease face additional challenges. James Gallagher talks to Emma Campbell, a mum of three young children who was diagnosed with bowel cancer at 36. Emma shares not just how her treatment affected her life, but the difficulties in advocating for herself as a younger person trying to get diagnosed. Professor Helen Coleman, cancer epidemiologist for Queens University Belfast, has been studying these diagnostic rates in younger people and explains possible reasons why more people like Emma are finding themselves living with the disease. A series of videos recently went viral on social media from women claiming their weight loss drugs got them pregnant. These drugs – like Ozempic and Wegovy – help people lose weight by suppressing appetite, but could they impact fertility? James speaks to Dr Charlotte Moffett, lecturer in Pharmacology and Molecular Pathology at the University of Ulster, who is studying if these drugs might alter someone's ability to conceive. James is also joined in the studio by GP, Dr Margaret McCartney, who helps him answer some of your questions. Presenter: James Gallagher Producer: Julia Ravey Content Editor: Holly Squire Production Coordinator: Elisabeth Tuohy TikTok credits: @Dkalsolive | @anastasiamalhotra | @coachkatierogers

Drs Michelle Kittleson and Evan Kransdorf talk about when to test, how genetic testing should be interpreted, and what to do with the results. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/997316). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Validating an Idiopathic Dilated Cardiomyopathy Diagnosis Using Cardiovascular Magnetic Resonance: The Dilated Cardiomyopathy Precision Medicine Study https://pubmed.ncbi.nlm.nih.gov/35240856/ Prevalence and Cumulative Risk of Familial Idiopathic Dilated Cardiomyopathy https://pubmed.ncbi.nlm.nih.gov/35103767 Family Heart Talk https://dcmproject.com/family-heart-talk/ Effectiveness of the Family Heart Talk Communication Tool in Improving Family Member Screening for Dilated Cardiomyopathy: Results of a Randomized Trial https://pubmed.ncbi.nlm.nih.gov/36938756/ Rare Variant Genetics and Dilated Cardiomyopathy Severity: The DCM Precision Medicine Study https://pubmed.ncbi.nlm.nih.gov/37641966/ Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology https://pubmed.ncbi.nlm.nih.gov/25741868/ Implications of Genetic Testing in Dilated Cardiomyopathy https://pubmed.ncbi.nlm.nih.gov/32880476/ Clinical Risk Score to Predict Pathogenic Genotypes in Patients With Dilated Cardiomyopathy https://pubmed.ncbi.nlm.nih.gov/36109106/ Screening for Dilated Cardiomyopathy in At-Risk First-Degree Relatives https://pubmed.ncbi.nlm.nih.gov/37225358/

Episode 224 of my Curate Your Health Podcast is out! Link below.   Dr. John Neustadt is here today to talk about bone health and osteoporosis. He explains how bone density tests are inadequate. He wants to educate people on how to improve your bone health and protect yourselves. Medications, such as antacids, are damaging bones and increasing the risk of fractures. Patients should discuss switching to safer medications with their provider. Also, reducing spicy foods, eating earlier in the evening, and shifting your position in bed, can help with acid reflux. To help strengthen your bones, he suggests exercise, resistance training and eating a healthy diet with high protein, whole grains, fruits and vegetables.    He can be found at: https://www.nbihealth.com/, https://www.facebook.com/nbihealth/, https://www.youtube.com/user/NBIHealth, https://www.linkedin.com/in/john-neustadt-nd-1553576/, and https://twitter.com/JohnNeustadt   Dr. John Neustadt has an international reputation as a doctor, researcher, and integrative medical expert. He became renowned in this field through his nutritional medicine research, clinical work, books he wrote, work with the FDA on evaluating the use of natural products for the potential treatment of rare diseases, developing million-dollar businesses, educating physicians on improving patient outcomes and the general public on how to make sure they're getting the care they need and the results they want, and as a medical expert advising businesses on product development and how to create superfans.   Dr. Neustadt has published more than 100 medical articles, written four health and wellness books and is now a #1 Amazon Best Selling Author in the field of Osteoporosis. His most recent book is, Fracture-Proof Your Bones: A Comprehensive Guide to Osteoporosis. Dr. Neustadt was also an editor of the textbook, Laboratory Evaluations for Integrative and Functional Medicine, which was used across the United States to train and educate physicians on using functional medicine with their patients.    Dr. Neustadt is a highly sought out speaker at medical conferences, he was recognized as one of the Top Ten Cited Authors in the world for his work. His research on integrative and functional medicine has been featured in the Natural Medicine Journal, Integrative Medicine: A Clinician's Journal, Holistic Primary Care, Molecular Nutrition & Food Research, and Experimental and Molecular Pathology.    Dr. Neustadt earned his naturopathic medical degree from Bastyr University where he was awarded the Founder's Award for academic and clinical excellence. He opened his clinic, Montana Integrative Medicine (MIM), in 2005 in Bozeman, Montana. He specialized in hard-to-treat, chronic degenerative diseases through an integrative approach that emphasized identifying and correcting the underlying causes of disease. For his clinical work, Dr. Neustadt was the first naturopathic doctor to be voted Best Doctor among all physicians in his area. When the award was announced, this is what the local newspaper had to say:  “It is noteworthy that Dr. Neustadt did not win ‘best naturopathic doctor;' he won best doctor.   Dr. Hammerstedt and her lifestyle coaching team can be found at www.wholisthealth.com and @wholisthealth on Facebook and Instagram as well as the Facebook group Curate Your Health. Wholist helps high performing women and men lose weight for the last time, with an innovative food and mindset coaching program to blueprint YOUR optimal body and mind, with real food, real work, real results...and no products or BS. Come curate YOUR sustainable health future, and personal and professional dynasty.   And remember, Who you choose to be Matters. You are valuable, You are worth this, You are your WholeYou.  

Caris Precision Oncology Alliance Chairman, Dr. Chadi Nabhan, sits down for an engaging podcast interview with Dr. David Braxton, Chief of Service for Molecular Pathology at Hoag Hospital in Newport Beach, California. Explore Dr. Braxton's remarkable career as a molecular pathologist and delve into the pivotal role molecular pathologists play in precision oncology, while examining the progressive integration of artificial intelligence within molecular pathology. For more information, please visit: www.CarisLifeSciences.com

Dr. Steven Quay is the founder of Seattle-based Atossa Therapeutics Inc., established in 2009. Prior to his work at Atossa, he served as Chairman of the Board, President and Chief Executive Officer of MDRNA, Inc., a biotechnology company focused on the development and commercialization of RNAi-based therapeutic products, from August 2000 to May 2008, and as its Chief Scientific Officer until November 30, 2008 (MDRNA, Inc. was formerly known as Nastech Pharmaceutical Company Inc. and is currently known as Marina Biotech, Inc.). Dr. Quay is certified in Anatomic Pathology with the American Board of Pathology, completed both an internship and residency in anatomic pathology at Massachusetts General Hospital, a Harvard Medical School teaching hospital, and is a former faculty member of the Department of Pathology, Stanford University School of Medicine.   Dr. Quay is a named inventor on 76 U.S. patents, 108 pending patent applications and is a named inventor on patents covering five pharmaceutical products that have been approved by the U.S. Food and Drug Administration. He received an M.D. in 1977 and a Ph.D. in 1975 from the University of Michigan Medical School. He also received his B.A. degree in biology, chemistry and mathematics from Western Michigan University in 1971. Dr. Quay is a member of the American Society of Investigative Pathology, the Association of Molecular Pathology, the Society for Laboratory Automation and Screening and the Association of Pathology Informatics.

On this week's episode, Rich Thayer and Mickey Urdea are exploring metagenomics with Dr. Rick Nolte, an engaging expert on the subject. Dr. Nolte helps to define what metagenomics is, its diagnostic uses, its advantages, and where the field is going. This is a delightfully in-depth interview about a complicated but important topic that is very much worth your time; please enjoy. Frederick (Rick) S. Nolte, PhD, is currently a Senior Director/Medical Advisor at Karius, the microbial cell free DNA company, and Professor Emeritus of the Department of Pathology and Laboratory Medicine at the Medical University of South Carolina. He served as Vice-Chair for Laboratory Medicine/Medical Director of Clinical Laboratories and Molecular Pathology. He is a Diplomate of the American Board of Medical Microbiology and a Fellow of the American Academy of Microbiology. Dr. Nolte completed his B.S. degree in Biology at the University of Cincinnati, and his Ph.D. in Medical Microbiology at the Ohio State University. Dr. Nolte completed a postdoctoral fellowship in Public Health and Medical Laboratory Microbiology at the University of Rochester. Prior to coming to MUSC in 2007, he spent 18 years at Emory University School of Medicine where he was a Professor of Pathology and Laboratory Medicine and Director of the Clinical Microbiology, Molecular Diagnostic, and Serology Laboratories at Emory Medical Laboratories. He is active in and held positions of responsibility in the American Society for Microbiology, Association for Molecular Pathology, Clinical and Laboratory Standards Institute, Infectious Diseases Society of America, American Society for Clinical Pathology, College of American Pathology and American Association for Clinical Chemistry. He has authored numerous book chapters, practice guidelines, and peer-reviewed publications in the areas of clinical microbiology and molecular diagnostics.

In this episode of “Lab Medicine Rounds,” Justin Kreuter, M.D., speaks with Laura Tafe, M.D., associate professor of pathology and laboratory medicine at Dartmouth-Hitchcock Medical Center and president of the Association of Molecular Pathology, to discuss practicing art and medicine.Timestamps:0:00 Intro01:30 What is your artist origin story?03:40 What does that relationship of your art practice and medical practice look like?07:18 How do you navigate the challenge of not having enough time?08:52 What advice do you have for healthcare professionals, new residents, who have interests in addition to medicine?12:37 What are your thoughts? Where does your art practice go in the coming months and years? 15:40 What is your interest in Graphic Medicine? (question from Dr. Tafe to Dr. Kreuter)20:04 Outro

This episode of the Thinking Health Podcast Features Dr. Ryan Fortna, President of Avero Diagnostics, Director of Molecular Pathology, and Scientific Director of ADx Health.Dr. Fortna did his PhD at the University of Pennsylvania in Cell and Molecular Biology and was focused on the cell biology of Alzheimer's disease, in particular the gamma secretase complex (which is the enzymatic protein complex responsible for converting APP (the protein version of the gene I mentioned on the podcast that is one of the three genes that can have mutations that cause Familial Alzheimer's) into A-beta (the protein fragment that causes amyloid plaques)).   Dr. Fortna is the Scientific Director at ADx Health which is a company focusing on genetic testing for Alzheimer's Disease operating under the motto, “Know your risk, reduce your risk”, believing that with knowledge comes the power to live a better life. Their goal is to develop and offer genetics and wellness products that provide actionable information to allow individuals to find balance, purpose, and thrive.   In this episode, we talk a lot about the genetic side of Alzheimer's disease going in-depth on the differences between deterministic and non-deterministic genes, APOE4, other important genes for Alzheimer's, and how lifestyle can be a powerful approach for combating your genes and reducing your risk of Alzheimer's.

On June 13, 2013, the Supreme Court issued its unanimous decision in Association for Molecular Pathology v. Myriad Genetics Inc. a case that would ban attempts to patent naturally occurring DNA sequences.Now, ten years down the line with a decade of hindsight, Dr. Roger Klein, who played a central role as an expert, advisor, and spokesperson for the Association for Molecular Pathology in AMP v. Myriad, joins us to discuss this important case. In this Explainer we discuss the context surrounding this case, the debates that arose, and the impact this rule had across the past 10 years. Featuring:Dr. Roger D. Klein, Faculty Fellow, Center for Law, Science & Innovation Sandra Day O'Connor College of LawVisit our website – www.RegProject.org – to learn more, view all of our content, and connect with us on social media.*******As always, the Federalist Society takes no position on particular legal or public policy issues; all expressions of opinion are those of the speaker.

As soaring testing costs, coverage challenges, and heavy administrative overhead continue to impact access to guideline-concordant screening and biomarker testing, hear what multidisciplinary care teams need to know about mitigating the financial burden of cancer diagnostics. In this episode, CANCER BUZZ speaks with Jan Nowak, MD, PhD and clinical chief of Molecular Pathology at Roswell Park Comprehensive Cancer Center, Alti Rahman, MHA, MBA, CSSBB and practice administrator at Oncology Consultants, and Jordan Karwedsky, financial counselor at St. Vincent Hospital Cancer Center Green Bay Oncology, on how to reduce financial hurdles and increase access to cancer diagnostics. “Understanding how coverage decisions and policies are made will help identify gaps in those policies, which can then be addressed…understanding this process can also enable productive appeals to payment denials when they occur.” – Jan Nowak, MD, PhD “The cancer screening process is a community-based approach; it is something that doesn't just belong to the healthcare provider or health system realm–it is an approach taken to educate various communities on the importance of screening.” – Alti Rahman, MHA, MBA, CSSBB This video podcast was produced in connection with the education program Cancer Diagnostics: Transforming Complex to Clear, with support by Bristol Myers Squibb, Merck, Lilly, AstraZeneca, and Amgen. Guests:  Clinician: Jan Nowak, MD, PhD Clinical Chief, Molecular Pathology, Roswell Park Comprehensive Cancer Center Buffalo, NY Administrator: Alti Rahman, MHA, MBA, CSSBB Practice Administrator Oncology Consultants Houston, TX Financial Counselor:   Jordan Karwedsky, Financial Counselor St. Vincent Hospital Cancer Center, Green Bay Oncology Green Bay, WI Resources: ACCC Financial Advocacy Network ACCC Updates Financial Advocacy Services Guidelines Financial Advocacy Playbook Financial Advocacy Toolkit LIVE from NOC: Advocates Weigh-In on Financial Advocacy Guidelines Update — [MINI PODCAST] LIVE from NOC: Financial Advocacy Guidelines — [MINI PODCAST]  

In this Amgen sponsored podcast, David R. Braxton, MD, Chief of Service for Molecular Pathology at Hoag Hospital, shares his insights as considerations on operationalizing biomarker testing into clinical practice in NSCLC. He discusses considerations on improving the turnaround time of test results, clinical application of ctDNA testing as well as strategies for documentation of results for ease of retrieval. Sponsored by Amgen

The topic of tritium continues to be a focal point for nuclear opponents, who use anti-science claims to stoke fear among a public they know does not, by and large, understand complex topics of radiation biology. Thus, to the victims of anti-nuclear ideology, the "science" behind tritium offers little comfort. Still, we try to do our best this week with radiation expert Dr. Geraldine Thomas. Dr. Geraldine Thomas is a senior academic and Chair in Molecular Pathology at the Faculty of Medicine of Imperial College London. She is an active researcher in fields of tissue banking and molecular pathology of thyroid and breast cancer, and the Director of the Chernobyl Tissue bank. Note: This episode is a rerun from April 2021. Original shownotes: The decision by the Japanese government to begin releasing 1.25 million tonnes of treated water from the Fukushima nuclear plant site over a 10 year period has caused a major stir not only amongst environmental NGO's but also regional countries with historic emnity to Japan. Greenpeace alleges that radionuclides released into the sea "may damage DNA of humans and other organisms." China states that "the release is extremely irresponsible and will pose serious harm to the health and sagety of people in neighbouring countries and the international community." So what are the politics and science behind the controversy? The Fukushima water has been treated and the almost all radio-isotopes have been removed except for tritium. Just how dangerous is it? Tritium is a weak beta emitter with 70x less energy then the the naturally occuring and ubiquitous intracellular radioisotope Potassium 40 which undergoes 4600 radioactive decays per second in our bodies. The health impacts of a radioisotope are multifactorial. The type of radiation emitted, the energy of that decay, the physical and biologic halflife of the isotope. The amount of tritium that one would need to drink to match a dose from something like a CT scan is simply impossible to ingest. In response to the Fukushima accident in an effort to gain the trust of the population Japan has already reset its regulatory limits for radiation in drinking water at 1/100th that of the EU. Are these efforts actually counter productive?

References:  Roy-Chowdhuri S, Dacic S, Ghofrani M, Illei PB, Layfield LJ, Lee C, Michael CW, Miller RA, Mitchell JW, Nikolic B, Nowak JA, Pastis NJ Jr, Rauch CA, Sharma A, Souter L, Billman BL, Thomas NE, VanderLaan PA, Voss JS, Wahidi MM, Yarmus LB, Gilbert CR. Collection and Handling of Thoracic Small Biopsy and Cytology Specimens for Ancillary Studies: Guideline From the College of American Pathologists in Collaboration With the American College of Chest Physicians, Association for Molecular Pathology, American Society of Cytopathology, American Thoracic Society, Pulmonary Pathology Society, Papanicolaou Society of Cytopathology, Society of Interventional Radiology, and Society of Thoracic Radiology. Arch Pathol Lab Med. 2020 May 13. doi: 10.5858/arpa.2020-0119-CP. Epub ahead of print. PMID: 32401054. Yatabe Y, Dacic S, Borczuk AC, Warth A, Russell PA, Lantuejoul S, Beasley MB, Thunnissen E, Pelosi G, Rekhtman N, Bubendorf L, Mino-Kenudson M, Yoshida A, Geisinger KR, Noguchi M, Chirieac LR, Bolting J, Chung JH, Chou TY, Chen G, Poleri C, Lopez-Rios F, Papotti M, Sholl LM, Roden AC, Travis WD, Hirsch FR, Kerr KM, Tsao MS, Nicholson AG, Wistuba I, Moreira AL. Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. J Thorac Oncol. 2019 Mar;14(3):377-407. doi: 10.1016/j.jtho.2018.12.005. Epub 2018 Dec 18. PMID: 30572031; PMCID: PMC6422775. Sehgal IS, Gupta N, Dhooria S, Aggarwal AN, Madan K, Jain D, Gupta P, Madan NK, Rajwanshi A, Agarwal R. Processing and Reporting of Cytology Specimens from Mediastinal Lymph Nodes Collected using Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration: A State-of-the-Art Review. J Cytol. 2020 Apr-Jun;37(2):72-81. doi: 10.4103/JOC.JOC_100_19. Epub 2020 Apr 2. PMID: 32606494; PMCID: PMC7315917. Wahidi MM, Herth F, Yasufuku K, Shepherd RW, Yarmus L, Chawla M, Lamb C, Casey KR, Patel S, Silvestri GA, Feller-Kopman DJ. Technical Aspects of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration: CHEST Guideline and Expert Panel Report. Chest. 2016 Mar;149(3):816-35. doi: 10.1378/chest.15-1216. Epub 2016 Jan 12. PMID: 26402427.

Dr. Praveen Vikas, Dr. Tyler Johnson, and Dr. Russell Broaddus present the ASCO endorsement of the Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: Guideline From the College of American Pathologists in Collaboration With the Association for Molecular Pathology and Fight Colorectal Cancer. They discuss key evidence-based recommendations, focusing on the appropriate modality of testing (immunohistochemistry, polymerase chain reaction, or next generation sequencing) across multiple cancer types. Additionally, they cover the ASCO endorsement process, points of emphasis raised by the ASCO expert panel, and implications for clinicians and patients. Read the full guideline endorsement, Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of CAP Guideline at www.asco.org/molecular-testing-and-biomarkers-guidelines.   TRANSCRIPT Brittany Harvey: Hello, and welcome, to the ASCO Guidelines podcast; one of ASCO's podcasts, delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at: asco.org/podcasts. My name is Brittany Harvey, and today, I'm interviewing Dr. Praveen Vikas from the University of Iowa, Dr. Tyler Johnson from Stanford University, and Dr. Russell Broaddus from the University of North Carolina; authors on, 'Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of CAP Guideline'. Thank you for being here, Dr. Vikas, Dr. Johnson, and Dr. Broaddus. Dr. Praveen Vikas: Sure. Dr. Tyler Johnson: Thanks for having us. Dr. Russell Broaddus: Thank you. Brittany Harvey: First, I'd like to note that ASCO takes great care in the development of its guidelines, and ensuring that the ASCO Conflict of Interest policy is followed for each guideline product. The full conflict of interest information for this guideline endorsement panel is available online with the publication of the guideline endorsement in the Journal of Clinical Oncology. To start, Dr. Vikas, do you have any relevant disclosures that are directly related to this guideline topic? Dr. Praveen Vikas: I don't. Brittany Harvey: And Dr. Johnson, do you have any relevant disclosures that are directly related to this guideline? Dr. Tyler Johnson: I do not. Brittany Harvey: And finally, Dr. Broaddus, do you have any relevant disclosures that are directly related to this guideline topic? Dr. Russell Broaddus: I do not. Brittany Harvey: Great. Thank you all for providing that information. So, starting us off on the content of this endorsement, Dr. Vikas, what is the scope of this guideline endorsement? Dr. Praveen Vikas: So, as you can see from the topic and headline, the guideline endorsement was focused on mismatch repair and microsatellite instability testing for immune checkpoint inhibitor therapy, and this is basically an endorsement by ASCO, of a guideline that was developed jointly by CAP, and others. Brittany Harvey: Great. And then you just mentioned that this is an endorsement of the guideline developed by CAP and other organizations. Can you provide us an overview of how this guideline endorsement process works? Dr. Praveen Vikas: ASCO definitely takes great pride in endorsing some of the guidelines that are relevant to our cancer community, and of course, mismatch repair and microsatellite instability testing has been one of those areas where there is a lack of clear guidance. So, when we were approached from CAP about endorsing this guideline, we definitely realized that there's not much published from most of our oncology community, so we were very excited about looking into this guideline and endorsing it. So, this was very much for a topic that we thought is very useful and very timely. Brittany Harvey: And that's great to hear. So then, Dr. Broaddus, as an author both on the guideline endorsement and as a member of the original guideline panel, what are the key recommendations of the CAP guideline? Dr. Russell Broaddus: So, there are six key recommendations from the College of American Pathologists guideline that ASCO recently endorsed. I like to think of the first four as being bundled together because they're interrelated - we dealt with these by cancer type for the first four. So, for colorectal cancer, there's by far the most published evidence on this type of testing, and the evidence-based guideline found that really did not matter so much whether you used immunohistochemistry, or PCR-based microsatellite instability analysis, or next-generation sequencing-based analysis to detect mismatch repair or microsatellite instability. The three different techniques are almost interchangeable in their metrics. Similarly, for gastroesophageal adenocarcinoma and small intestinal adenocarcinoma, immunohistochemistry and PCR-based MSI are very, very similar. There's not quite enough published evidence to equate next-generation sequencing. There were one or two very, very good papers with limited number of patients. The guideline committee felt like if there was maybe one or two more published papers in this space, that for gastroesophageal adenocarcinoma and small bowel adenocarcinoma, it would be similar to colorectal adenocarcinoma, whereas the three techniques were nearly interchangeable. After that, unfortunately, the published evidence really drops off in both quantity and quality for almost all other cancer types. So, endometrial cancer, there's quite a bit of literature. Most of it really points to the immunohistochemistry outperforms PCR-based MSI analysis and PCR-based next-generation sequencing analysis. Most likely, that's because these PCR-based approaches nearly always are optimized to detect mismatch repair defects in colorectal cancer, or other GI types of cancer. And there's actually very good published evidence that this detection of mismatch repair can be cancer-type specific. So, the recommendation is to use immunohistochemistry for endometrial cancer. Fourth recommendation for all other cancer types not encompassed by those first three recommendations, the committee recommends to choose a laboratory-based approach to detect mismatch repair or microsatellite instability defects, but there is no good published evidence to suggest which is the best approach. And again, like with endometrial cancer, there's evidence that the PCR-based approaches, which are usually optimized for colorectal cancer and GI-type cancers, may not be sufficient to work well with cancer types outside of the GI tract. So, almost by default, the recommendation is to choose immunohistochemistry. Fifth recommendation: Many people tend to equate microsatellite instability and high tumor mutation burden. For sure, in colorectal cancer and other GI tract cancers, these two entities, there is substantial overlap. But for cancer types outside of the GI tract, you can easily have a tumor that has a mismatch repair defect, or high levels of microsatellite instability and not have high tumor mutation burdens. So, the recommendation is to not equate those two entities. And finally, last recommendation is that for all of us to remember that these defects in DNA mismatch repair or microsatellite instability, are also hallmarks of hereditary cancer syndrome - Lynch syndrome, and that if you identify unexpectedly that a patient with an advanced cancer has one of these defects and DNA mismatch repair, to consider the possibility of Lynch syndrome, and to alert the appropriate care team, for those patients' family members can be screened as well. Brittany Harvey: Understood. Thank you for reviewing those evidence-based recommendations made by the CAP panel, and then endorsed by the ASCO panel. So, were there any additional points of discussion or emphasis raised by the ASCO endorsement panel? Dr. Russell Broaddus: Yes. And very appropriately, I believe. One-- and this is purely because of the issue of scope, and not to minimize the importance of these issues. One issue that the CAP guideline did not address was the important issue of pre-analytic variables and how they can impact diagnostic testing. A second issue, again, not considered by the CAP evidence-based guideline group, because of just tremendous scope problems, is how do these tests - immunohistochemistry, PCR-based MSI analysis, PCR-based next-generation sequencing analysis - how do we incorporate their use with PD-L1 immunohistochemistry, for example? Liquid biopsies, as a second example. Should we have a staged approach in assessing tumors with all these different testing modalities? And frankly, the answer is, we don't know right now. I think this represents an excellent area where oncologists and pathologists can actually work to provide the evidence in some specific cancer types on whether multiple modalities provide benefit compared to just one modality. Brittany Harvey: Definitely, those are key points perhaps for future research, and I appreciate you explaining what was in and out of scope of this guideline. So then following that, Dr. Johnson, in your view, what is the importance of this guideline endorsement, and how will it affect ASCO members? Dr. Tyler Johnson: I think to understand the importance of this particular endorsement, it's helpful to zoom the lens out to 30,000 feet for a minute. Pretty much, all oncologists, I think remember 10 or 12 years ago, the types of drugs that we now commonly use for immunotherapy, burst onto the scene with the treatment of melanoma. And those trials were quite remarkable because previous to that, not only did we not have a cure for metastatic melanoma, we hardly had a treatment for metastatic melanoma. We had really almost nothing to offer those patients. And then there was this, initially a small and then a larger, and then a much larger series of patients, who we now know with 10 or 12 years of follow up, that many patients who were treated with immunotherapy, who had metastatic melanoma were actually cured. Not just treated but cured. So, in the decade or so since then, there has been this understandable and appropriate stampede of trying to figure out, "Okay, how do we use similar drugs in all of the other many metastatic tumor types?" And I think to generalize a lot, and to make overly simple a very complicated picture, what has emerged from that is that unfortunately for many metastatic solid tumors, immunotherapy just doesn't do much. It's essentially inert, as best we can tell clinically. But there is a small percentage of patients, exactly what percentage depends on the tumor type and the genetic analysis as we're talking about here, but there's a small percentage, maybe 10-20% of patients, who derive this unbelievable benefit from immunotherapy in metastatic solid tumors, to the point that some of those patients, including in other solid tumors, not just melanoma, appear to be functionally cured by the administration of immunotherapy. And so, the question of course that has resulted from that, is if eight or nine patients are going to get no benefit and maybe even harm from administration of immunotherapy, but one or two patients out of 10 is going to get this really remarkable benefit, it would be so great if we could be much more specific in knowing which patients are going to derive benefit, and which patients are not going to derive any benefit and may even be harmed. And I think that that's the context within which we have to understand this guideline endorsement, is that this is getting us one step further to knowing which patients are likely to get benefit from immunotherapy in metastatic solid tumors. And the really nice thing, as Russell pointed out, is that one kind of shorthand takeaway from this is that it is almost never wrong to look at the question with immunohistochemistry. And that's a great answer, because it is also almost always the most readily available test. And so, if you have a patient who has a metastatic solid tumor and you order immunohistochemistry to look for microsatellite instability, that's almost regardless of the tumor type, it's probably going to give you a reliable answer. And if it shows that they're microsatellite unstable, then that means that that patient, regardless of the tumor type, really probably should get immunotherapy upfront or very close to upfront. And then there are more nuances sort of beyond that. But I think that's really the take home message, that this gives us one powerful tool for discerning who is likely to get benefit from these therapies. Brittany Harvey: Absolutely. That's a key thought that you just mentioned, that this is about delivering personalized medicine to individual patients. So then, you've already touched on this a bit in your last answer, but finally, to wrap us up, how will these recommendations impact patients with cancer being considered for immune checkpoint inhibitor therapy? Dr. Tyler Johnson: I think that many clinical oncologists have the experience that when you sit down to talk to a patient who has newly diagnosed metastatic cancer, what their treatment is going to be, almost all of them have heard about immunotherapy somewhere; in the newspaper, or from friends, or in a cancer support group or whatever. So, most of them want to know what part, if any, immunotherapy is going to play in the care of their cancer right upfront. And I think this gets us one step closer to being able to answer that question. Now, the one thing that-- and Russell touched on this a little bit, but I think it's just important to highlight, this gives us an important way to predict people who are going to respond, but that does not necessarily mean that people who this does not identify as likely responders are therefore not going to respond. And that gets into a much more complicated question that depending on the tumor type, you may have to look at PD-L1 expression, or other things. So, it's just to say that this is not a comprehensive, definitive answer, but it is one important part of the answer. I don't know if Russell or Praveen wants to add any more thoughts about that, but that's kind of how I would contextualize this. Dr. Russell Broaddus: I think where there's a lot of opportunity here for us to start developing the evidence on the utility or not, of such staged approaches that if-- say like, immunohistochemistry does not reveal a mismatch repair defect, should we, for some of these cancer types where we don't routinely assess PD-L1, should we next do PD-L1 immunohistochemistry? And if that doesn't show overexpression, should we next try next-generation sequencing approach? Because sometimes those don't overlap with immunohistochemistry. So, I think there's a lot of room for us to provide this evidence. Dr. Praveen Vikas: Yeah. And one point I would like to add, we had a lot of discussion among our ASCO endorsement panel, was that by recommending IHC or PCR over NGS in certain cancer, there would be scenarios where NGS will be needed, because NGS would tell us a lot more, like HER2 amplifications, and that was our point of discussion. We wanted to make sure that we send that message that even in cases where IHC and PCR is being done, that we may still have additional need for NGS testing. Dr. Tyler Johnson: Yeah. Thank you, Praveen, for that. I should qualify, just to make sure that it's clear, that when I said that IHC is a good go-to, I only meant in terms of testing for this specific thing. Part of the problem with next gen sequencing is that it often takes 4-6 weeks, and so I think the practical approach is, you should send the next-generation sequencing, but in the meantime, you can do the IHC to have an answer to that particular question, and usually in one or two days, depending on the lab, and then the next gen sequencing can come back whenever it comes back, and then you can use that for directing later lines of therapy. Brittany Harvey: Excellent. Well, I've really enjoyed this discussion today, and I want to thank you all for your work on this guideline endorsement, and thank you for your time today, Dr. Vikas, Dr. Johnson and Dr. Broaddus. Dr. Praveen Vikas: Thanks so much, Brittany. Dr. Russell Broaddus: Thank you. Dr. Tyler Johnson: Appreciate the time. Brittany Harvey: And thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to: www.asco.org/molecular-testing-and-biomarkers-guidelines.  You can also find many of our guidelines and interactive resources in the free ASCO guidelines app, available in the Apple App store or the Google Play store. If you have enjoyed what you've heard today, please rate and review the podcast, and be sure to subscribe, so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy, should not be construed as an ASCO endorsement.  

Dr. John Neustadt has an international reputation as a researcher and integrative medical expert. Dr. John became renowned in this field through his nutritional medicine research, clinical work, books, and work with the FDA on evaluating the use of natural products for the potential treatment of rare diseases, developing million-dollar businesses educating physicians on improving patient outcomes, and the general public on how to make sure they're getting the care they need and the results they want! In this episode, Tee and Dr. John discuss the importance of achieving sleep naturally and cover some of the simple techniques that John uses with his patients to achieve this process. Dr. John also unpacks some of the biological processes of sleep and why it is so vital for healing, wellness, focus, and mental health. Dr. Neustadt is a highly sought-after speaker at medical conferences, he was recognized as one of the Top Ten Cited Authors in the world for his work. Dr. John's research on integrative and functional medicine has been featured in the Natural Medicine Journal, Integrative Medicine: A Clinician's Journal, Holistic Primary Care, Molecular Nutrition & Food Research, and Experimental and Molecular Pathology.  Dr. Neustadt earned his naturopathic medical degree from Bastyr University where he was awarded the Founder's Award for academic and clinical excellence. He opened his clinic, Montana Integrative Medicine (MIM), in 2005 in Bozeman, Montana. He specialized in hard-to-treat, chronic degenerative diseases through an integrative approach that emphasized identifying and correcting the underlying causes of disease. For his clinical work, Dr. Neustadt was the first naturopathic doctor to be voted Best Doctor among all physicians in his area. When the award was announced, this is what the local newspaper had to say: “It is noteworthy that Dr. Neustadt did not win ‘best naturopathic doctor;' he won the best doctor.  Discount for Listeners: 30% discount on all NBI products to listeners. Simply use the NBI30 coupon code during checkout in the NBI store. The discount will combine with the quantity discounts, allowing people to save even more money!   Connect With Dr. John Email: DrNeustadt@NBIHealth.com  Phone: (858) 527-5459  Website: NBIHealth.com  Twitter: https://twitter.com/JohnNeustadt Facebook: https://www.facebook.com/nbihealth/ Youtube: https://www.youtube.com/@NBIHealth _______________________________________________ Follow Therese "Tee" Forton-Barnes and The Green Living Gurus: Tee's Organics - Therese's Healthy Products for You and Your Home: https://thegreenlivinggurus.com/shop-tees-organics/ The Green Living Gurus Website: https://thegreenlivinggurus.com/ Instagram: https://www.instagram.com/greenlivinggurus/ Youtube: https://www.youtube.com/channel/UCW7_phs1GZUPzG21Zgjnqtw Facebook: https://www.facebook.com/GreenLivingGurus Healthy Living Group on Facebook Tip the podcaster! Support Tee and the endless information that she provides: Patreon: https://www.patreon.com/TheGreenLivingGurus Venmo: @Therese-Forton-Barnes last four digits of her cell are 8868 For further info contact Tee: Email: Tee@TheGreenLivingGurus.com Cell: 716-868-8868

World Diabetes Day takes place each year in the month of November, created to raise awareness about the disease.  Diabetes is a global health threat diabetes with the number of people living with diabetes continuing to rise. Diagnostic testing is one of the major tools to help prevent and manage the disease.    About our Speaker: Dr. Amy L. Pyle earned her Ph.D. in Molecular Pathology from Vanderbilt University. Following graduate school, Dr. Pyle completed a post-doctoral fellowship in Clinical Chemistry at Vanderbilt University. Dr. Pyle took a position as Assistant Director of Core Laboratories at Nationwide Children's Hospital in 2011. Throughout her training, Dr. Pyle published multiple abstracts, papers, and book chapters, and has received numerous awards for her contributions to the scientific community.

“If we are serious about this quintuple aim, this lofty goal of improved health outcomes at lower cost with better experiences for our patients, all of that in an environment of equity and physician wellbeing, then we really need a shift in health and healthcare. Because what I see is that patients are disenchanted with healthcare. They don't feel that their physicians have time for them. They don't feel heard. And I see physicians leaving healthcare because the system is really not conducive to either group.” - Dr. Iris Schrijver  Dr. Iris Schrijver is a certified lifestyle medicine physician who also specializes in clinical pathology and molecular genetics. She's an adjunct clinical professor of pathology at Stanford University School of Medicine and a past president of the Association for Molecular Pathology. Dr. Schrijver has served as the medical director for a volunteers in medicine organization because she believes that health care is a basic human right. Together with her husband, an astrophysicist, she wrote Living with the Stars, a popular science book about connections between the human body and the universe. And more recently, she has written On the Path to Health, Wellbeing and Fulfillment. Originally from the Netherlands, Dr. Schrijver eventually landed at Stanford to be trained in clinical molecular genetics and clinical pathology, or laboratory medicine. She then became a faculty member in the pathology department where her main purpose was to direct the diagnostic molecular genetic pathology lab. After a long and rewarding career there, she and her husband made a joint decision to step away and pursue new adventures. They moved from California to Oregon where Dr. Schrijver became involved in a free clinic and ultimately became its medical director. She also discovered lifestyle medicine and was so impressed with its urgency and the science behind it that it inspired her to become certified in it herself. Her experience also inspired her to write her latest book. Dr. Schrijver shares just how important lifestyle medicine is and that it has a solid base in science. She explains the six pillars of health, well-being, and fulfillment and what they mean for both physicians and their patients. We discuss how to sift through all of the information that is out there and how small shifts add up to big, lasting changes. It can be challenging for physicians to “walk the walk” when it comes to lifestyle medicine, and Dr. Schrijver offers her advice. She also shares practical ways for physicians to integrate lifestyle medicine principles into their daily practice. What's Inside: How Dr. Schrijver became involved in lifestyle medicine. The six pillars of health, well-being, and fulfillment. How to integrate lifestyle medicine into your personal life and professional practice. Mentioned In This Episode: DocWorking.com American College of Lifestyle Medicine LifestyleForHealthandWellness.com IrisMD@Stanford.edu On the Path to Health, Wellbeing, and Fulfilment: To Your Health Find full transcripts of DocWorking: The Whole Physician Podcast episodes on the DocWorking Blog The past few weeks have been busy at DocWorking! We have been working behind the scenes to add even more CME credits to the THRIVE memberships. Let your CME budget help you prioritize your own wellness so you can get on with living your best life on your own terms, as defined by you, with DocWorking THRIVE. You can take the first step today by taking our 2 Minute Balance to Burnout Quiz! Where are you on the Balance to Burnout Continuum? Take the quiz and find out today! DocWorking empowers physicians and entire health care teams to get on the path to achieving their dreams, both in and outside of work, with programs designed to help you maximize life with minimal time. If you like our podcast and would like to subscribe and leave us a 5-star review, we would be extremely grateful! We're everywhere you like to get your podcasts! Apple iTunes, Spotify, iHeart Radio, Google, Pandora, Stitcher, PlayerFM, ListenNotes, Amazon, YouTube, Podbean. You can also find us on Instagram, Facebook, LinkedIn, and Twitter. Some links in our blogs and show notes are affiliate links, and purchases made via those links may result in payments to DocWorking. These help toward our production costs. Thank you for supporting DocWorking: The Whole Physician Podcast!

Professor Jorge Contreras, James T. Jensen Endowed Professor for Transactional Law and Director of the Program on Intellectual Property and Technology Law at the University of Utah S.J. Quinney College of Law, discusses the legal impact of patenting human genes, especially as it relates to the 2013 SCOTUS decision in Association for Molecular Pathology v. Myriad Genetics. Also discussed is the introduced "Patent Eligibility Restoration Act of 2022," which would explicitly overturn the Supreme Court's ruling in Myriad. Produced and Hosted by A J. Kierstead Check out his book, "The Genome Defense: Inside the Epic Legal Battle to Determine Who Owns your DNA"at https://www.amazon.com/gp/product/B08WK73TZR/ref=dbs_a_def_rwt_hsch_vapi_tkin_p1_i0  Read his aritcle "Another Legislative Attempt to Revive Gene Patenting" in the Harvard Law Petrie-Flom Center blog, Bill of Health: https://blog.petrieflom.law.harvard.edu/2022/08/04/another-legislative-attempt-to-revive-gene-patenting/ Get an email when the latest episode releases and never miss our weekly episodes by subscribing on Apple Podcast, Google Play, Stitcher, and Spotify! UNH Franklin Pierce School of Law is now accepting applications for JD and Graduate Programs at https://law.unh.edu  Legal topics include

In this episode, our host Dr. Swikrity U Baskota (@baskotacytopath), founder of www.matchtopath.com discusses the Electronic Residency Application Service® (ERAS®) pathology residency process with our expert panelists. The speakers include Dr. Thomas Cummings (@tjcmd888) Professor of Pathology, Director of Neuropathology and Ophthalmic Pathology and Residency Program Director at Duke University, North Carolina,  Dr. Carlos Pagan (@CAPaganPath) Assistant Professor of Surgical and Molecular Pathology and Residency Program Director at Columbia University, Dr. Clarissa Jordan (@pathcejmd), PGY-3 resident at Mayo Clinic, Future hematopathology fellow at Mayo Clinic and Dr. Melissa Meija Bautista (@Melissa_MB91), PGY-4 resident at Northwestern University, Future Pediatric pathology Fellow at Boston Children's Hospital and future neuropathology fellow at Northwestern University, Chicago.    Join us to learn more about the 2023 ERAS application timeline. What is a program looking for in a candidate's application? How can you strengthen your ERAS CV, and personal statement? How can you ensure your application is ready before the deadline...and many other tips shared by our expert guests!    Reference: ERAS® 2023 Residency Timeline | Students & Residents (aamc.org)   MatchtoPath: www.matchtopath.com Twitter: @matchtopath;  Instagram, Facebook and LinkedIn: matchtopath   

Why does what we eat matter for our health and wellbeing? "The more fruits and veggies you eat, the more you do for your health, your longevity, your happiness, it even lifts your mood." Dr. Iris Schrijver is a certified Lifestyle medicine physician, specializing in clinical pathology and molecular genetics. She's an adjunct clinical professor of pathology at the Stanford University School of Medicine and a past president of the association for Molecular Pathology. Dr. Schrijver served as Medical Director of Clackamas Volunteers in Medicine and is now developing a lifestyle medicine service there. Because she believes that healthcare is a basic human right, her dedication to patients in medical progress through science has resulted in the publication of many original research articles, book chapters, and books. Together with her husband and astrophysicist, she wrote “Living with the Stars”, a popular science book about connections between the human body and the universe. Her goal is to make sure that everyone can get high-quality health care via lifestyle medicine. In this conversation, Dr. Iris discusses the impact of lifestyle factors and happiness on health and longevity. She shares her journey from Genetics & Pathology to Lifestyle Medicine and how medicine is shifting with its new approach. She explains homeostasis and ways to prevent cancer by early detection. She talks about why good health matters and the typical timespan between disease diagnosis & discovery. She also shares what impacts our health the most: food, exercise, or genes. She explains how happiness contributes to health and longevity, how to be really happy despite challenges, the role of money in happiness, and why happy people live longer. She also touches upon the key lessons from the 75-year-old study on health and happiness. She highlights four factors that reduce lifespan - smoking & alcohol, lack of physical activity, the way we eat, and obesity. Tune in to learn more! In this episode, you will learn:The science behind health and well beingThe importance of lifestyle in maintaining healthThe meaning of homeostasis and how to determine itThe six pillars of lifestyle medicine and how to apply themThe connection between body and mind in health and well being Resources:Learn more about Iris and her new book at https://lifestyleforhealthandwellness.comYou can access the Kindle edition here: https://www.amazon.com/dp/B0B7X269S5 Loved this episode? Leave us a review and rating here: https://podcasts.apple.com/us/podcast/the-whole-health-cure/id1395016604?mt=2 This podcast is brought to you by Emory Lifestyle Medicine & Wellness. To learn more about our work, please visithttps://bit.ly/EmoryLM

In this episode, Jorge L. Contreras, Professor of Law at the University of Utah College of Law, discusses his book "The Genome Defense: Inside the Epic Legal Battle to Determine Who Owns Your DNA," which is published by Algonquin Books. Contreras describes the landmark Supreme Court patent case Association for Molecular Pathology v. Myriad Genetics and explains why it was important. He recounts the story of the case and how he reported on it. And he reflects on what it can tell us about patent policy.This episode was hosted by Brian L. Frye, Spears-Gilbert Professor of Law at the University of Kentucky College of Law. Frye is on Twitter at @brianlfrye. See acast.com/privacy for privacy and opt-out information.

Liquid biopsy has emerged as a novel diagnostic tool, enabling rapid, non-invasive molecular testing of thyroid cancers. This episode offers insight into some of the opportunities and challenges that are presented by liquid biopsy in this field. To answer questions on this topic, we have invited Professor Frederique Penault-Llorca to join us. She is Professor of Pathology at the University of Clermont-Ferrand and CEO of the Comprehensive Regional Cancer Institute Centre Jean Perrin in Clermont-Ferrand, France. Funding Information: This episode is supported by an educational grant from Eli Lilly, who have had no influence on the content or choice of faculty. Faculty Disclosures: Professor Frederique Penault-Llorca has disclosures are as follows: Advisory board: Roche, EliLilly, Illumina, Speaker: Roche, EliLilly, Illumina, References 1. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–1214 2. Albarel F, Conte-Devolx B, Oliver C. From nodule to differentiated thyroid carcinoma: Contributions of molecular analysis in 2012. Ann Endocrinol (Paris). 2012;73:155–164 3. Nylen C, Mechera R, Marechal-Ross I, et al. Molecular markers guiding thyroid cancer management. Cancers (Basel). 2020;12:2164 4. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Thyroid Carcinoma. Version 2.2022. May 5, 2022. Available at: https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf (accessed June 2022) 5. Pinchot SN, Al-Wagih H, Schaefer S, et al. Accuracy of fine-needle aspiration biopsy for predicting neoplasm or carcinoma in thyroid nodules 4 cm or larger. Arch Surg. 2009;144:649–655 6. Bellevicine C, Sgariglia R, Nacchio M, et al. Molecular testing of thyroid fine-needle aspiration: local issues and solutions. An interventional cytopathologist perspective. J Mol Pathol. 2021;2:233–240 7. Kasraeian S, Allison DC, Ahlmann ER, et al. A comparison of fine-needle aspiration, core biopsy, and surgical biopsy in the diagnosis of extremity soft tissue masses. Clin Orthop Relat Res. 2010;468:2992–3002 8. Lindeman NI, Cagle PT, Aisner DL, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: Guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med. 2018;142:321–346 9. Pennell NA, Arcila ME, Gandara DR, et al. Biomarker testing for patients with advanced non-small cell lung cancer: Real-world issues and tough choices. Am Soc Clin Oncol Educ Book. 2019;39:531–542 10. Belli C, Penault-Llorca F, Ladanyi M, et al. ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research. Ann Oncol. 2021;32:337–350 11. Li MM, Datto M, Duncavage EJ, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: A joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017;19:4–23

Author and certified lifestyle medicine physician, Iris Schrijver, MD, describes a fulfilling and fast-paced academic career at Stanford as a full professor of pathology and director of a molecular genetics research lab. A few years ago, in an unlikely turn of events, an opportunity to design a leadership project ignited her long simmering interest in wellbeing.That project culminated in a 2016 research article An Exploration of Key Issues and Potential Solutions that Impact Physician Wellbeing and Professional Fulfilment at an Academic Center. I give you the details here because this is the article that led me to reach out to Dr. Schrijver a few years ago. I had read everything and everyone with a scholarly approach to physician burnout in preparation for several podcasts. Dr. Schrijver's article was one of the most outstanding and useful of the scores of articles I read. In our conversation, she describes how important it was for her to be a physician as she interviewed her colleagues about the underpinnings of burnout. She also describes how extrinsic factors, such as restricted autonomy, dominated the findings which contributed to physician burnout.She and her husband, an astrophysicist, decided there was more they wanted to accomplish and experience beyond their fulfilling but all-consuming careers. The magnificent Oregon landscape was pulling them away.Dr. Schrijver describes how she consciously made changes to create the life she wanted. She decided to pursue a certificate in lifestyle medicine, write a book on wellbeing, and contribute to medicine and patients in a different way. They moved to Clackamas County, Oregon, and she began volunteer work at the Clackamas Volunteers in Medicine Clinic—including a stint as medical director and a board member. Now she is developing a lifestyle medicine service for the Clinic. She finds the work remarkably rewarding. As she says, “Poverty is not a crime, and it is a privilege to provide good medical care for this population.” She continues to serve as adjunct pathology faculty at Stanford.Dr. Schrijver describes an interaction with a mentor early in her career who gave her a pointed introduction to her leadership accountabilities as a physician. It served her well. She has served in academic and national leadership roles, including as the President of the Association for Molecular Pathology.She connects the scientific method, physician leadership, and physician wellbeing to the important task of promulgating accurate and useful information to the public. Dr. Schrijver makes a compelling case in her book and in our conversation that we can take steps to improve wellbeing. We can envision and create a more fulfilling life for ourselves and guide our patients to greater wellbeing as well.Also in this episode:•The Six Principles of Lifestyle Medicine•Mentoring advice to physicians making their first career move•Does Press Ganey turn doctors into Nordstrom clerks?•How alliances can serve physicians in attaining wellbeing•Seeking resilience is aiming too low—aim to thriveMeet Iris Schrijver, MDIris Schrijver is a certified lifestyle medicine physician, also specialized in clinical pathology and molecular genetics. She is an adjunct clinical professor of pathology at the Stanford University School of Medicine and a past president of the Association for Molecular Pathology. Dr. Schrijver served as medical director of Clackamas Volunteers in Medicine, and is now developing a lifestyle medicine service there, because she believes that healthcare is a basic human right. Her dedication to patients and to medical progress through science has resulted in the publication of many original research articles, book chapters, and books. Together with her husband, an astrophysicist, she wrote “Living with the stars”, a popular science book about connections between the human body and the Universe. Her passion for lifestyle medicine, science, education, and the possibility of wellbeing for everyone sparked her latest work: "On the Path to Health, Wellbeing, and Fulfilment: To Your Health". This book investigates the basis of what we think we know about healthy living, and reveals the influences on the use and understanding of health information. It shows how scientific breakthroughs shed light on health, causes of disease, and overall wellbeing throughout life.Iris lives and works near Portland, Oregon, and enjoys the great outdoors of the Pacific Northwest. Learn more about Iris and her new book at lifestyleforhealthandwellness.com.Other Resources: Clackamus Volunteers in Medicine https://clackamasvim.org/An Exploration of Key Issues and Potential Solutions that Impact Physician Wellbeing and Professional Fulfillment at an Academic Center https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4793321/

Roger D. Klein, MD,JD (@RogerDKlein) is an expert in Health and Law with the Regulatory Transparency Project's FDA and Health working group. He is a former Medical Director of Molecular Pathology at the Cleveland Clinic and former adviser to the FDA, CDC, HHS and CMS. Federal Mask Mandate for Travel

On Episode 9 of The Game-Changing Women of Healthcare, Meg is joined by Dr. Sabine Linn, professor of translational oncology focusing on breast cancer at Utrecht University and a practicing medical oncologist at the Netherlands Cancer Institute.The two discuss Dr. Linn's work in biomarker research, the immunological aspects of breast cancer, advancements in cancer diagnostics and how they can help personalize cancer treatment, the patience and perseverance necessary to complete cancer research studies, Dr. Linn's love of sports as meditation, her vision for achieving equality in her field and beyond, and much more. About Dr. Sabine LinnDr. Sabine Linn is a professor of translational oncology focusing on breast cancer at Utrecht University and a practicing medical oncologist at the Netherlands Cancer Institute. She received her Ph.D. on multidrug resistance in solid tumors from the Free University of Amsterdam. Dr. Linn was awarded a Dutch Cancer Society Research Fellowship in 2000 and developed two conditional knock-out mouse models, for both non-small cell lung cancer and small cell lung cancer, in close collaboration with Dr. Ralph Meuwissen in the laboratory of Dr. A.J. Berns at the Netherlands Cancer Institute in Amsterdam.She has also been a group leader at the Division of Molecular Pathology at the Netherlands Cancer Institute since 2005, where she and her research group focus on the molecular dissection of breast cancer by differential drug sensitivity.Further Reading:Mouse model for lung tumorigenesisSummary of Dr. Linn's ResearchKate Raworth and Doughnut EconomicsWe Should All Be FeministsNo More Boys and GirlsEdith Eger: The Choice and The GiftEpisode Credits: The Game-Changing Women of Healthcare is a production of The Krinsky Company. Hosted by Meg Escobosa. Produced, edited, engineered, and mixed by Calvin Marty. Theme music composed and performed by Calvin Marty. Intro and outro voiced by John Parsons. ©2022 The Krinsky Company

Ann Moyer is Associate Professor of Laboratory Medicine and Pathology at Mayo Clinic, Rochester, Minnesota, USA.Manuel Salto-Tellez is Professor of Molecular Pathology at Queen's University Belfast, Northern Ireland, and Professor of Integrated Pathology at the Institute of Cancer Research in London, UK.

Dr. Geraldine Thomas, a professor of Molecular Pathology at Imperial College London specializing in thyroid cancer and the Director of the Chernobyl Tissue Bank, joins me to discuss the phenomenon of “radiation vacations” for children believed to have been affected by the Chernobyl accident.  Chernobyl Children International (CCI) has organized close to 1 million such trips for children from Ukraine and Belarus with the claim that these vacations extend these children's lives by on average 2 years. It also supports a number of orphanages and social services in Belarus. In Ireland CCI is one of the most successful charities in the country's history having fundraised over 100 million euros to date. https://www.chernobyl-international.com/ Dr. Thomas gives an overview of the science behind transgenerational effects of radiation and assesses the scientific and medical reasoning behind claims specific to Chernobyl. Dr. Thomas also explains the very real impact of thyroid cancer upon a specific age group of children exposed to high levels of Iodine 131 during a narrow time interval after the accident and what their medical treatment involves. It is estimated that 16,000 additional thyroid cancers will occur within this age group with a mortality of 1%.    We discuss the harm that radiophobia is capable of causing, illustrated in part by a critique of the Academy Award winning 2003 documentary, “Chernobyl Heart” which features Adi Roche the founder of CCI. https://youtu.be/jFwGEsJg2MI

Can human genes be patented and owned? That's the question behind Jorge Contreras' book "The Genome Defense." The author and professor of law at the University of Utah tells the story of the 2013 Supreme Court case Association for Molecular Pathology v. Myriad Genetics. The longshot case, brought by the ACLU, challenged the right to patent human genes, a practice that had been used by biotech companies for decades.   Learn more about your ad choices. Visit megaphone.fm/adchoices

Veľa z nás spí zle. A to nie je dobre, pretože spánok ako základná ľudská potreba slúži napríklad na to, aby sme sa opravili. A aj keď ide o banálne tvrdenie, skrýva sa za ním obrovský problém, ktorý sa okrem veľkého počtu jednotlivcov týka verejného zdravia, a tým pádom aj verejných financií. Jeho následky sa niekde vyrátavajú v percentách HDP. Odborná obec upozorňuje, že až 90 percent duševných porúch je spojených s poruchami spánku a tam sa, bohužiaľ, zoznam zdravotných následkov nekončí. Ako si spanie zlepšiť, existujú skratky a pomáhajú pri tom rôzne aplikácie, nové technológie či výživové doplnky? Tomáš Eichler je neurogenetik, ktorý pôsobí vo Viedni v Research Institute of Molecular Pathology a Konrad Lorenz Institute for Evolution and Cognition Research. Objasnil mechanizmy spánku a zobúdzania sa červov, no a práve s ním sa Nikola Šuliková Bajánová o význame spánku a trikoch, ako si ho zlepšiť, rozpráva v dnešnej epizóde.  –  Ak máte pre nás spätnú väzbu, odkaz alebo nápad, napíšte nám na dobrerano@sme.sk  –  Všetky podcasty denníka SME nájdete na sme.sk/podcasty  –  Podporte vznik podcastu Dobré ráno a kúpte si digitálne predplatné SME.sk na sme.sk/podcast  –  Odoberajte aj denný newsletter SME.sk s najdôležitejšími správami na sme.sk/brifing –  Ďakujeme, že počúvate podcast Dobré ráno.

Nuclear energy has now been recognized by a UN expert committee as the lowest carbon intensity of any major energy source. Anyone who has been involved in climate advocacy will have heard the common refrain ‘what about Chernobyl and Fukushima?' We all know about the Chernobyl nuclear disaster.  It caused roughly 100 deaths and thousands of cases of preventable thyroid cancer.  But what about Fukushima Daiichi? In this episode I will summarize my interviews with several nuclear and radiation health experts on the subject. Dr Philip Thomas is a professor of risk management at University of Bristol. Dr. Thomas has extensive experience in the chemical and nuclear industries and is co-author of the NREFS study which developed an objective method of risk assessment in nuclear accidents. Dr. Gerry Thomas is Professor of Molecular Pathology at Imperial College London, and an expert on the molecular biology of thyroid cancer. She established the Chernobyl tissue bank in 1998, and is an author of a number of reviews of the health effects of radiation exposure following nuclear accidents, having contributed to IAEA publications on the Fukushima accident UNSCEAR publications on the Chernobyl accident. Geochemist and Energy scientist Dr. James Conca is Senior Scientist for UFA Ventures, Inc. in the Tri-Cities, Washington, an Adjunct Professor at Washington State University in the School of the Environment, a Trustee of the Herbert M. Parker Foundation, an Affiliate Scientist at Los Alamos National Laboratory and a Science Contributor to Forbes on energy and nuclear issues. Join me at https://www.therationalview.ca Come check out my YouTube channel and join our Facebook discussion group. Twitter:@AlScottRational Instagram: @The_Rational_View #therationalview #podcast #fukushima #nuclearenergy #meltdown #greenenergy #cleanenergy #radiation #tsunami #evacuation #cancer

#007 On today's episode of all things, con amor, we are joined by Dr. Stacey Fanning, PhD. Dr. Fanning completed her PhD in Immunology and Molecular Pathology and fully breaks down the COVID vaccine for us. She answers questions we have all been wondering and serves as an incredible source of knowledge. We answer a few things such as: is the vaccine safe, was it rushed, could it affect fertility, can you still get COVID once vaccinated, among others. Be sure to share this episode with anyone that may share these questions or concerns as we answer them with a true expert. Find us on instagram: https://www.instagram.com/stephaniearnouk/ https://www.instagram.com/allthingsconamor/ --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

The Rational View episode 43 discusses the public misperceptions of nuclear radiation health risks, as presented in the UNSCEAR reports on Chernobyl and Fukushima Daiichi. Dr. Gerry Thomas is Professor of Molecular Pathology at Imperial College London and, until 2016 was Clinical Director of the newly established West London NHS Genomic Medicine Centre. She is a serial biobanker, having established the Chernobyl Tissue Bank in 1998. She was the Scientific Director of the Wales Cancer Bank, and was Project Director for the Imperial College Healthcare Tissue. She was awarded an OBE in 2019 for services to Science and Public Health. Her scientific research has been focused on thyroid cancer. She has carried out research into the health effects of the Chernobyl accident since 1992. Gerry has published extensively on the molecular pathology of thyroid cancer, and is an author of a number of reviews of the health effects of radiation exposure following nuclear accidents, having contributed to IAEA publications on the Fukushima accident, UNSCEAR publications on the Chernobyl accident and more recently an IARC review of Thyroid Monitoring after nuclear accidents. Follow me on https://therationalview.podbean.com Join the discussion https://facebook.com/groups/therationalview Twitter https://twitter.com/AlScottRational Insta http://instagram.com/the_rational_view #therationalview #podcast #greenenergy #nuclearenergy #climatechange #nuclearfornetzero #atomicenergy #evidencebased #energy

In this episode of The Breakdown, Elise and Juliana explore how the teenage brain develops and the science behind it, along with how schools can cultivate a healthy learning environment. We interview Christina Swan, Ph.D. in Molecular Pathology and co-founder of Waterloo School in Austin, TX., and ask her about why Waterloo School is doing school differently.

Today's episode, we have Wilfred Daye, who was a former head of quantitative trading in UBS Investment Bank. Starting his career as a CMBS desk analyst at Lehman Brothers, Wilfred combined his interest in trading and his scientific quantitative background into making his a name in the industry. If you look at his career so far, you would be impressed like us. Having three different degrees, one is Ph.D in Molecular Pathology from University of Southern California (USC), Wilfred has dedicated himself a lot in science, which later evolved into his sharp perspective into this competitive trading and quantitative financial market. Besides his scientific academic background, Wilfred shared to us his opinion on business lending, his experience of working in UBS and Lehman Brothers, and his opinion on current technology and finanical world.If you would like to know what's working as head of quantitative trading in UBS and Wilfred Daye's future projects, you shouldn't want to miss this episode.